{
  "meta": {
    "title": "00013_Late_Night_Pyq_Pyt_Marathon_-_13",
    "url": "https://brainandscalpel.vercel.app/00013-late-night-pyq-pyt-marathon-13-be1bdd8a.html",
    "scrapedAt": "2025-11-29T17:24:29.526Z"
  },
  "questions": [
    {
      "id": 13955,
      "choices": [
        {
          "id": 55781,
          "text": "<p><span style=\"font-size:12.0pt;\">CVP (central venous pressure)</span></p>"
        },
        {
          "id": 55782,
          "text": "<p><span style=\"font-size:12.0pt;\">Urine Output</span></p>"
        },
        {
          "id": 55783,
          "text": "<p><span style=\"font-size:12.0pt;\">Blood pressure</span></p>"
        },
        {
          "id": 55784,
          "text": "<p><span style=\"font-size:12.0pt;\">Oxygen saturation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which parameter is best used to monitor the adequacy of and guide fluid resuscitation in a patient? (AIIMS MAY 2017)</span></p>",
      "unique_key": "Q2708096",
      "question_audio": null,
      "question_video": null,
      "map_id": 12136909,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Urine Output</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Urine output is the best measure of organ perfusion and the best monitor for adequacy of fluid resuscitation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Adequate end-organ perfusion is best indicated by urine output of &gt;0.5 to 1 mL/kg/h. However, it does not give minute-to-minute values.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. CVP (central venous pressure)</strong>: CVP is a poor reflector of preload. Central venous pressure (CVP) is the mean pressure in the superior vena cava, indicating right ventricular end-diastolic pressure or preload. Normal CVP ranges from 2 to 7 mm Hg (3 to 9 cm H20). A sick or injured patient with a CVP &lt;3 mm Hg is presumed to be volume depleted and maybe given fluids with relative safety. However, CVP is unreliable for assessment of volume status or left ventricular function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Blood pressure</strong>: Blood pressure is an important vital sign, but it alone may not provide a complete picture of a patient's fluid status. Hypotension (low blood pressure) can be a late sign of inadequate fluid resuscitation, and normotension (normal blood pressure) does not guarantee adequate tissue perfusion. The level of consciousness is an important marker for cerebral perfusion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Oxygen saturation</strong>: Oxygen saturation (SpO2) measures the amount of oxygen in the blood, and while it is essential for assessing respiratory status, it is not a direct indicator of fluid balance or adequacy of fluid resuscitation</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Urine output is a valuable and non-invasive parameter for assessing fluid resuscitation. Adequate urine output indicates that the patient's kidneys are functioning well and that they are likely receiving an appropriate amount of fluids. It is a practical and real-time measure of the patient's response to fluid therapy.</span></p>",
      "correct_choice_id": 55782,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19952,
      "choices": [
        {
          "id": 79769,
          "text": "<p><span style=\"font-size:12.0pt;\">Tachypnea</span></p>"
        },
        {
          "id": 79770,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypotension</span></p>"
        },
        {
          "id": 79771,
          "text": "<p><span style=\"font-size:12.0pt;\">Sweating</span></p>"
        },
        {
          "id": 79772,
          "text": "<p><span style=\"font-size:12.0pt;\">Red hot skin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old farmer was brought to the emergency after he suddenly became unconscious while working in the field. On examination, his temperature was 105 degrees Fahrenheit and his skin turgor was decreased. Which of the following would not be seen in the patient?&nbsp;&nbsp;(NEET PG 2023)</span></p>",
      "unique_key": "Q9670835",
      "question_audio": null,
      "question_video": null,
      "map_id": 12136910,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. Sweating</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In the scenario described, the patient likely suffers from <strong>heatstroke</strong>, characterized by a high body temperature (105°F), altered consciousness, and dehydration (indicated by decreased skin turgor).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Heatstroke</strong> is a severe form of heat illness that occurs when the body's heat-dissipating mechanisms fail. One of the classic signs, especially in exertional heatstroke, is the cessation of sweating, despite the elevated body temperature. This lack of sweating is due to dehydration and the body's inability to maintain adequate heat loss through evaporation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A: Tachypnea</strong> - Rapid, deep breathing (Kussmaul breathing) can be seen in heatstroke</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B: Hypotension</strong> - Dehydration and vasodilation in an attempt to dissipate heat can result in hypotension in heatstroke.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D: Red hot skin</strong> - Heatstroke patients can present with hot, flushed skin due to increased blood flow to the skin surface and the body's inability to dissipate heat effectively.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Difference between Fever and Heatstroke is as follows:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/27/screenshot-2024-05-27-132125.png\" alt=\"\" width=\"1000\" height=\"644\"></span></p>",
      "correct_choice_id": 79771,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52361,
      "choices": [
        {
          "id": 208937,
          "text": "<p><span style=\"font-size:12.0pt;\">Resting zone</span></p>"
        },
        {
          "id": 208938,
          "text": "<p><span style=\"font-size:12.0pt;\">Proliferative zone</span></p>"
        },
        {
          "id": 208939,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypertrophic zone</span></p>"
        },
        {
          "id": 208940,
          "text": "<p><span style=\"font-size:12.0pt;\">Zone of provisional calcification</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Salter Harris Type 1 injury passes through which zone?&nbsp;</span>&nbsp;(INICET MAY 2024)</p>",
      "unique_key": "Q7207983",
      "question_audio": null,
      "question_video": null,
      "map_id": 12136911,
      "difficulty_level": "intermediate",
      "subjects_id": [
        15
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Hypertrophic zone&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>SALTER HARRIS CLASSIFICATION&nbsp;</strong></span></p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">The <strong>arrangement of cells of the physis</strong> is in layers or zones.&nbsp;</span></li><li><span style=\"font-size:16px;\">These layers&nbsp;include the <strong>reserve, proliferative and hypertrophic</strong> zones.&nbsp;</span></li><li><span style=\"font-size:16px;\">The <strong>reserve zone</strong> serves as the <strong>storage area</strong> for lipids, proteoglycans, and glycogen for growth and&nbsp;<strong>matrix production</strong> later.&nbsp;</span></li><li><span style=\"font-size:16px;\">The <strong>proliferative zone</strong> has the <strong>highest rate of extracellular matrix production</strong> and accounts for the <strong>most abundant longitudinal growth</strong>.&nbsp;</span></li><li><span style=\"font-size:16px;\">The <strong>hypertrophic zone has three phases</strong>:&nbsp;</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:16px;\"><strong>Maturation</strong> allows for preparation for calcification</span></li><li><span style=\"font-size:16px;\"><strong>Degenerative</strong> further prepare the matrix</span></li><li><span style=\"font-size:16px;\"><strong>Provisional calcification zone</strong> is where chondrocyte death occurs, allowing for <strong>calcium release</strong>.&nbsp;</span></li></ul></li><li><span style=\"font-size:16px;\"><strong>Physeal fractures</strong>&nbsp;most commonly occur in the <strong>zone of provisional calcification</strong>, as it is the <strong>weakest</strong> in response to shearing stress.&nbsp;</span></li><li><span style=\"font-size:16px;\">The physis is weaker than ligaments or periosteum in children, causing injury to the growth plate before other structures.&nbsp;</span></li><li><span style=\"font-size:16px;\"><strong>Zones of physis:</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-08-13%20155714.jpeg\" width=\"845\" height=\"771\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/25/screenshot-2024-07-25-131600.jpg\" alt=\"\" width=\"700\" height=\"788\"></strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Salter and Harris described two major types of epiphyseal plates</strong>: the <strong>pressure</strong> epiphysis and the <strong>traction</strong> epiphysis.&nbsp;</span></li><li><span style=\"font-size:16px;\"><strong>Pressure epiphyses provide longitudinal growth</strong>, at the end of long bones, are <strong>intra-articular</strong>, and <strong>bear weight</strong>.&nbsp;</span></li><li><span style=\"font-size:16px;\"><strong>Traction epiphyses provide appositional growth</strong>, at the origin or insertion of muscles, are <strong>extra-articular</strong>, and <strong>do not bear weight</strong>.&nbsp;</span></li><li><span style=\"font-size:16px;\">Their classification focuses on injuries at pressure epiphyses.&nbsp;</span></li><li><span style=\"font-size:16px;\">They recognized that physeal fractures consistently occur through the same histologic plane called the <strong>zone of provisional calcification</strong>.&nbsp;</span></li><li><span style=\"font-size:16px;\">This zone, <strong>located in the zone of hypertrophy</strong>, represents a <strong>transitional point between calcified and non-calcified extracellular matrix proteins</strong>, making it <strong>weaker</strong> than its surrounding osseous-ligamentous structures, and therefore <strong>more susceptible to injury.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/25/screenshot-2024-07-25-131827.jpg\" alt=\"\" width=\"700\" height=\"243\"></strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:16px;\">In <strong>type I injury</strong>, there is <strong>slip of epiphysis</strong> with <strong>damage to the hypertrophic zone</strong> of the physis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Resting zone:</strong> It is affected in storage disorders like Gaucher’s disease.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Proliferative zone:</strong> It is affected in growth hormone defects like Larsen’s syndrome.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Zone of provisional calcification:</strong> It is affected in mineralization defects like rickets.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\">Hypertrophic zone of the physis has a high bone turnover.&nbsp;</span></li><li><span style=\"font-size:16px;\">It is the area where all Salter-Harris injuries occur.&nbsp;</span></li><li><span style=\"font-size:16px;\">Thus, the Type I injuries occurs in the hypertrophic zone of the physis.&nbsp;</span></li></ul>",
      "correct_choice_id": 208939,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56326,
      "choices": [
        {
          "id": 224717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase coronary blood flow by dilating the epicardial coronary arteries</span></span></span></p>"
        },
        {
          "id": 224718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce heart rate and myocardial oxygen demand</span></span></span></p>"
        },
        {
          "id": 224719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Block calcium channels to prevent coronary artery spasm</span></span></span></p>"
        },
        {
          "id": 224720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibit platelet aggregation within coronary arteries</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with a history of episodic chest pain at rest presents to the emergency department with complaints of chest tightness that typically occurs in the early morning hours. His ECG shows transient ST-segment elevation during episodes, and he is diagnosed with Prinzmetal angina. The patient is started on sublingual nitroglycerin, which promptly relieves his symptoms. To provide longer-term control, his cardiologist prescribes isosorbide mononitrate. After starting the medication, the patient reports a significant reduction in the frequency of his chest pain episodes. What is the primary mechanism by which nitrates alleviate symptoms in Prinzmetal angina?</span></span></span></p>",
      "unique_key": "Q4836374",
      "question_audio": null,
      "question_video": null,
      "map_id": 12136932,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Increase coronary blood flow by dilating the epicardial coronary arteries</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrates, such as isosorbide mononitrate, act as potent vasodilators by releasing nitric oxide, which relaxes vascular smooth muscle. In Prinzmetal angina, the primary pathology is a transient spasm of the coronary arteries, which reduces blood flow to the heart muscle. Nitrates directly counter this by dilating the epicardial coronary arteries, thereby increasing blood flow, enhancing oxygen delivery to the myocardium, and alleviating chest pain. This direct vasodilatory effect is the cornerstone of symptom relief in patients with Prinzmetal angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Reduce heart rate and myocardial oxygen demand</span></strong><span style=\"font-size:12.0pt\">: Nitrates can reduce myocardial oxygen demand modestly due to their effect on venodilation, which decreases preload. However, this is not their primary mechanism of action in Prinzmetal angina, where coronary vasodilation is the key therapeutic effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Block calcium channels to prevent coronary artery spasm</span></strong><span style=\"font-size:12.0pt\">: This mechanism pertains to calcium channel blockers, which also treat Prinzmetal angina by preventing smooth muscle contraction in the coronary arteries. Nitrates, however, do not block calcium channels but rather promote smooth muscle relaxation through nitric oxide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibit platelet aggregation within coronary arteries</span></strong><span style=\"font-size:12.0pt\">: Antiplatelet agents like aspirin and clopidogrel act through this mechanism, but nitrates do not have a significant effect on platelet aggregation. Their primary action is vasodilation rather than directly influencing platelet function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrates, such as isosorbide mononitrate, alleviate Prinzmetal angina by dilating the coronary arteries, countering arterial spasm, and increasing myocardial blood flow. Recognizing the specific mechanisms of action of drugs helps guide appropriate treatment choices for conditions involving coronary artery spasms.</span></span></span></p>",
      "correct_choice_id": 224717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10157,
      "choices": [
        {
          "id": 40594,
          "text": "<p><span style=\"font-size:12.0pt;\">Continue breastfeeding and observe</span></p>"
        },
        {
          "id": 40595,
          "text": "<p><span style=\"font-size:12.0pt;\">Admit to NICU</span></p>"
        },
        {
          "id": 40596,
          "text": "<p><span style=\"font-size:12.0pt;\">Start artificial feeding</span></p>"
        },
        {
          "id": 40597,
          "text": "<p><span style=\"font-size:12.0pt;\">Start intravenous fluids</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 1-day-old neonate has not passed urine since birth. What is the next step in management? (NEET PG 2022)</span></p>",
      "unique_key": "Q4331909",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137033,
      "difficulty_level": "beginner",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Continue breastfeeding and observe</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">A 1-day-old neonate not passing urine since birth is a normal finding in neonates. Continuing breastfeeding and observation is the next step in management.</span></li><li><span style=\"font-size:12.0pt;\">Delay in passing urine or stool is a cause for concern and requires investigation.</span></li></ul><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/28/picture137.jpg\" alt=\"\" width=\"1000\" height=\"724\"></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/28/picture138.jpg\" alt=\"\" width=\"1000\" height=\"589\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Admit to NICU:&nbsp;</strong>This is not necessary as the absence of urination within the first 24 hours can be normal. Admission to NICU is reserved for cases where the neonate shows signs of distress or other serious conditions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Start artificial feeding:&nbsp;</strong>This option is incorrect as breastfeeding should be continued unless there is a clear medical indication to switch to artificial feeding.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Start intravenous fluids:&nbsp;</strong>Starting IV fluids is not necessary unless the child shows signs of dehydration or is unable to take fluids orally.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">It is normal for a neonate to not pass urine within the first 24 hours; continue breastfeeding and observe the baby.</span></p>",
      "correct_choice_id": 40594,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24762,
      "choices": [
        {
          "id": 99009,
          "text": "<p><span style=\"font-size:11.0pt;\">Azithromycin</span></p>"
        },
        {
          "id": 99010,
          "text": "<p><span style=\"font-size:11.0pt;\">Ceftriaxone plus azithromycin</span></p>"
        },
        {
          "id": 99011,
          "text": "<p><span style=\"font-size:11.0pt;\">Amoxicillin plus clavulanic acid</span></p>"
        },
        {
          "id": 99012,
          "text": "<p><span style=\"font-size:11.0pt;\">Piperacillin Tazobactam plus ciprofloxacin</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A patient in emergency has the following lab parameters: creatinine 1.5 and BUN 45. The chest x-ray is shown below. In gram staining and culture only, rhinovirus was isolated. The patient is shifted to ICU. What is the treatment of choice in this patient? (INICET MAY 2023)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/13/whatsapp-image-2024-09-13-at-103848-am_uLaNUaB.jpeg\" alt=\"\" width=\"300\" height=\"212\"></span></p>",
      "unique_key": "Q9499007",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137035,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B)&nbsp;Ceftriaxone plus azithromycin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The patient is diagnosed with <strong>community-acquired pneumonia (CAP)</strong> and has been shifted to the ICU. The treatment of choice for ICU-admitted patients with CAP includes a <strong>beta-lactam antibiotic</strong> like beta-lactam/beta-lactamase inhibitor (BL/BLI) combination like amoxicillin-clavulanic acid or piperacillin-tazobactam, or a third-generation cephalosporin like ceftriaxone combined with azithromycin or a respiratory fluoroquinolone such as levofloxacin or moxifloxacin should be administered.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Ceftriaxone are used to cover typical bacteria, while azithromycin covers atypical bacteria and provides additional anti-inflammatory properties.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Azithromycin</strong>: Insufficient as monotherapy in ICU settings.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Amoxicillin plus clavulanic acid:</strong> Lacks coverage for atypical pathogens alone.</span><br>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Piperacillin Tazobactam plus ciprofloxacin</strong>: Ciprofloxacin is not a respiratory fluoroquinolone.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The combination of a beta-lactam antibiotic and azithromycin is the treatment of choice for ICU-admitted patients with community-acquired pneumonia.</span></p>",
      "correct_choice_id": 99010,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5959,
      "choices": [
        {
          "id": 23806,
          "text": "<p><span style=\"font-size:12pt;\">Methotrexate with folinic acid</span></p>"
        },
        {
          "id": 23807,
          "text": "<p><span style=\"font-size:12pt;\">Methotrexate</span></p>"
        },
        {
          "id": 23808,
          "text": "<p><span style=\"font-size:12pt;\">EMACO regimen</span></p>"
        },
        {
          "id": 23809,
          "text": "<p><span style=\"font-size:12pt;\">Hysterectomy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A woman who underwent dilatation and curettage for molar pregnancy 6 months ago presents with persistent symptoms of abdominal pain and distention. On further evaluation, the beta- hCG levels were persistently elevated and cannonball foci were found on the chest X-ray. What is the appropriate management in this case? (NEET PG 2021)</span></p>",
      "unique_key": "Q1012895",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137036,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Methotrexate with folinic acid</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Methotrexate with folinic acid:</strong> This is a clear case of post-molar choriocarcinoma with lung metastases. Treatment is based on prognostication and staging. According to the given scoring system, the parameters such as the time interval since the antecedent pregnancy, beta-hCG levels, and the presence of lung metastases suggest a low-risk choriocarcinoma. For low-risk choriocarcinoma, the recommended treatment is multi-dose single-agent chemotherapy with methotrexate. Methotrexate is administered in a multi-dose regimen (Day 1, 3, 5, 7) alternating with folinic acid (Day 2, 4, 6, 8).</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/1.jpg\" alt=\"\" width=\"1000\" height=\"643\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">&lt; 6: LOW RISK</span></li><li><span style=\"font-size:12pt;\">&gt; 7 HIGH RISK</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Methotrexate:</strong> Methotrexate alone might be considered for very low-risk cases. However, in this case, with persistent elevated beta-hCG levels and lung metastases, a multi-dose regimen along with folinic acid is preferred to enhance efficacy and reduce toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. EMACO regimen:</strong> The EMACO regimen, which includes etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine, is used for high-risk choriocarcinoma. This patient's score indicates a low-risk profile, making EMACO unnecessary and more toxic than needed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Hysterectomy:</strong> Hysterectomy is not the first line of treatment for choriocarcinoma, especially in the context of low-risk metastatic disease. It may be considered in cases of heavy bleeding or when the disease is confined to the uterus and chemotherapy is not effective.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Low-risk choriocarcinoma post-molar pregnancy with lung metastases is treated with a multi-dose regimen of methotrexate alternating with folinic acid</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page 789, Williams Gynecology, 3<sup>rd</sup> edition</strong></span></p>",
      "correct_choice_id": 23806,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11053,
      "choices": [
        {
          "id": 44178,
          "text": "<p><span style=\"font-size:18px;\">Response- Mitigation- Reconstruction- Rehabilitation- Preparedness</span></p>"
        },
        {
          "id": 44179,
          "text": "<p><span style=\"font-size:18px;\">Mitigation- Rehabilitation- Reconstruction- Preparedness- response</span></p>"
        },
        {
          "id": 44180,
          "text": "<p><span style=\"font-size:18px;\">Response- Rehabilitation- Reconstruction- Mitigation- Preparedness</span></p>"
        },
        {
          "id": 44181,
          "text": "<p><span style=\"font-size:18px;\">Mitigation- Preparedness- Reconstruction- Rehabilitation- Response</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>As a physician on a disaster preparedness committee in a region prone to natural disasters, you are discussing the appropriate sequence of actions following a disaster. Which of the following sequences correctly represents the appropriate steps in disaster management after the event has taken place? </strong><i><strong>[AIIMS MAY 2018]</strong></i></span></p>",
      "unique_key": "Q1160149",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137037,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (c) Response – Rehabilitation – Reconstruction – Mitigation – Preparedness</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">The correct sequence after a disaster as per the general disaster management principles is:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\"><strong>Response:</strong> Immediate actions taken to ensure safety, provide emergency services, and stabilize the situation. This involves –</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:18px;\">Search, rescue and first aid</span></li><li><span style=\"font-size:18px;\">Field care</span></li><li><span style=\"font-size:18px;\">Triage</span></li><li><span style=\"font-size:18px;\">Tagging</span></li><li><span style=\"font-size:18px;\">Identification of dead</span></li></ul></li><li><span style=\"font-size:18px;\"><strong>Rehabilitation:</strong> Short-term recovery and normalization of operations to restore basic services and functions in the affected area.</span></li><li><span style=\"font-size:18px;\"><strong>Reconstruction:</strong> Long-term rebuilding of infrastructure and restoration of a fully functional community.</span></li><li><span style=\"font-size:18px;\"><strong>Mitigation:</strong> Efforts to reduce the risk and lessen the impact of future disasters.</span></li><li><span style=\"font-size:18px;\"><strong>Preparedness:</strong> Planning and preparation to improve response activities for future disasters.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Disaster Cycle</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/20/whatsapp-image-2023-10-20-at-173957.jpeg\" alt=\"\" width=\"500\" height=\"534\"></span></p>",
      "correct_choice_id": 44180,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 43272,
      "choices": [
        {
          "id": 172755,
          "text": "<p><span style=\"font-size:12pt;\">Rinne’s test positive , Weber’s test lateralized to left ear</span></p>"
        },
        {
          "id": 172756,
          "text": "<p><span style=\"font-size:12pt;\">Rinne’s test positive , Weber’s test lateralized to right ear</span></p>"
        },
        {
          "id": 172757,
          "text": "<p><span style=\"font-size:12pt;\">Rinne’s test negative , Weber’s test lateralized to left ear</span></p>"
        },
        {
          "id": 172758,
          "text": "<p><span style=\"font-size:12pt;\">Rinne’s test negative , Weber’s test lateralized to right ear</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presents to the OPD with bilateral hearing loss with worsened right ear hearing loss. On examination, the doctor diagnose Otosclerosis and recommends stapedectomy as a final resort to the problem. What would be the findings of tuning fork tests based on which the doctor has recommended stapedectomy? (INICET Nov 2023)</span></p>",
      "unique_key": "Q2381221",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137038,
      "difficulty_level": "intermediate",
      "subjects_id": [
        9
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. D) Rinne’s test negative, Weber’s test lateralized to right ear</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Rinne’s test negative</strong>: Typical of otosclerosis, indicating conductive hearing loss where BC &gt; AC.</span></li><li><span style=\"font-size:16px;\"><strong>Weber’s test lateralized to right ear</strong>: Indicates that the sound is heard better in the ear with more conductive loss, which matches otosclerosis more severely affecting the right ear.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Rinne’s test positive, Weber’s test lateralized to left ear:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Rinne’s test positive</strong>: Indicates that air conduction (AC) is better than bone conduction (BC), which is a normal finding and typically not expected in conductive hearing loss like otosclerosis.</span></li><li><span style=\"font-size:16px;\"><strong>Weber’s test lateralized to left ear</strong>: In a case of unilateral or asymmetric hearing loss, Weber's test lateralizes to the better hearing ear in sensorineural hearing loss and to the poorer ear in conductive hearing loss. This pattern does not fit otosclerosis affecting the right ear more severely.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Rinne’s test positive, Weber’s test lateralized to right ear:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Rinne’s test positive</strong>: Again, indicates normal AC &gt; BC, not typical for otosclerosis.</span></li><li><span style=\"font-size:16px;\"><strong>Weber’s test lateralized to right ear</strong>: Would suggest either a sensorineural hearing loss on the left ear or less likely conductive loss on the right, which doesn’t match typical otosclerosis findings.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Rinne’s test negative, Weber’s test lateralized to left ear:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Rinne’s test negative</strong>: Indicates that BC &gt; AC, suggesting conductive hearing loss, typical of otosclerosis.</span></li><li><span style=\"font-size:16px;\"><strong>Weber’s test lateralized to left ear</strong>: Would imply the left ear is either better or has conductive loss, not aligning with greater hearing loss in the right ear due to otosclerosis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The combination of a negative Rinne test and Weber test lateralizing to the ear with more hearing loss is indicative of conductive hearing loss in that ear. In otosclerosis, the ossification of the stapes leads to mechanical dysfunction, preventing effective sound transmission, hence a stapedectomy might be recommended to mechanically bypass the ossified stapes and improve hearing.</span></p>",
      "correct_choice_id": 172758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5301,
      "choices": [
        {
          "id": 21176,
          "text": "<p><span style=\"font-size:12.0pt;\">P. falciparum</span></p>"
        },
        {
          "id": 21177,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. malariae</span></p>"
        },
        {
          "id": 21178,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. ovale</span></p>"
        },
        {
          "id": 21179,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. vivax</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a 30-year-old female from a tribal area who presents with fever for the last 3 days, which of the following is the most likely causative agent of her illness based on the diagnosis of malaria made through examination of the peripheral smear?</span><span style=\"font-size:10.5pt;\"> (</span><span style=\"font-size:12.0pt;\">NEET PG 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/01/1_vgK36SJ.jpg\" alt=\"\" width=\"300\" height=\"267\"></span></p>",
      "unique_key": "Q4731687",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137039,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) P. falciparum</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image shows ring forms/ early trophozoites in erythrocyte, which are binucleate (double chromatin) resembling <strong>stereo headphones</strong> in appearance, characteristic of P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">There may be several rings present within a single erythrocyte. The rings are often attached to the margins of the red cells and are described as form <u>applique or accole</u>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. P. malariae:</strong> Causes quartan malaria with a longer incubation period and typically presents with band-form trophozoites across the red cells, distinct from the forms seen in P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. P. ovale:</strong> Known for causing tertian malaria with similar clinical presentations to P. vivax, including the presence of Schüffner's dots and slightly enlarged and ovale-shaped erythrocytes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. P. vivax:</strong> Also causes tertian malaria, characterized by Schüffner's stippling in erythrocytes, larger ring forms than P. falciparum, and less severe disease outcomes compared to P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Identification of P. falciparum through the presence of distinctive ring forms in red blood cells on a peripheral smear is crucial for rapid initiation of appropriate antimalarial therapy, particularly in endemic regions. Early treatment is vital to prevent severe complications and reduce the morbidity and mortality associated with this malaria species.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/0004_zwS4Chh.png\" width=\"737\" height=\"826\"></p>",
      "correct_choice_id": 21176,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56327,
      "choices": [
        {
          "id": 224721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Saxagliptin</span></span></span></p>"
        },
        {
          "id": 224722,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin</span></span></span></p>"
        },
        {
          "id": 224723,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vildagliptin</span></span></span></p>"
        },
        {
          "id": 224724,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sitagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is safe to administer in patients with renal failure? (AIIMS NOV 2016)</span></span></p>",
      "unique_key": "Q8514981",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137090,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin is particularly suitable for use in patients with renal failure because it does not require dose adjustment in this condition. Unlike other drugs in the same class (DPP-4 inhibitors), linagliptin has a unique pharmacokinetic profile that allows it to be excreted largely unchanged in the bile and gut, rather than by the kidneys. This makes it safer for use in patients with compromised renal function, where other similar drugs might accumulate to toxic levels or require careful dose adjustments.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Saxagliptin:</span></strong><span style=\"font-size:12.0pt\"> requires dose adjustments in patients with renal impairment to avoid potential toxicity due to reduced clearance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vildagliptin:</span></strong><span style=\"font-size:12.0pt\"> also necessitates dose modifications in renal failure to prevent accumulation and potential adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sitagliptin:</span></strong><span style=\"font-size:12.0pt\"> must be dosed according to renal function, with lower doses needed as renal impairment increases to prevent undue drug accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Educational Objective:</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Linagliptin does not require dose adjustments in patients with renal impairment, making it a safe choice in the management of type 2 diabetes in this population.</span></span></span></p>",
      "correct_choice_id": 224722,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11105,
      "choices": [
        {
          "id": 44386,
          "text": "<p><span style=\"font-size:18px;\">1, 2&nbsp;</span></p>"
        },
        {
          "id": 44387,
          "text": "<p><span style=\"font-size:18px;\">2, 3&nbsp;</span></p>"
        },
        {
          "id": 44388,
          "text": "<p><span style=\"font-size:18px;\">3, 4&nbsp;</span></p>"
        },
        {
          "id": 44389,
          "text": "<p><span style=\"font-size:18px;\">1, 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>An internist in India is seeing a patient from a minority cultural and linguistic group. To foster therapeutic alliance and provide the best care possible, which of the following approaches should the physician prioritize? [</strong><i><strong>INICET MAY 2022]</strong></i></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\"><strong>Insist on good communication.</strong></span></li><li><span style=\"font-size:18px;\"><strong>Insist on communication only via an interpreter.</strong></span></li><li><span style=\"font-size:18px;\"><strong>Treat them regardless of their cultural perceptions.</strong></span></li><li><span style=\"font-size:18px;\"><strong>Consider the patient's religion and cultural perception.</strong></span></li></ol>",
      "unique_key": "Q3473732",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137131,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (d) 1, 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\">To foster a strong therapeutic alliance and provide high-quality care, the physician should prioritize the following:</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>1. Insist on good communication:</strong> Effective communication is crucial for building a strong doctor-patient relationship. Good communication helps in understanding the patient's concerns, explaining medical conditions and treatment options clearly, and ensuring that the patient feels heard and respected.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>4. Consider the patient's religion and cultural perception:</strong> Culturally competent care involves acknowledging and respecting the patient's cultural, religious, and linguistic background. This approach ensures that care is tailored to meet the specific needs and values of the patient, which can enhance their comfort and trust in the healthcare system.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>2. Insist on communication only via an interpreter:</strong> Incorrect. While good communication is essential, insisting on communication only via an interpreter may not always be necessary or preferred by the patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>3. Treat them regardless of their cultural perceptions:</strong> Incorrect. Treating patients regardless of their cultural perceptions does not align with providing culturally competent care, which aims to respect and incorporate cultural differences into the care plan.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">The communication skills of physicians are an effective step of making effective relationship between doctor and patient</span></li><li><span style=\"font-size:18px;\">Research has shown that the way patients perceive their connection with their physician significantly influences their sense of satisfaction and level of concern about their health</span></li><li><span style=\"font-size:18px;\">The goal of culturally competent health care services is to provide the highest quality of care to every patient, regardless of race, ethnicity, cultural background</span></li></ul>",
      "correct_choice_id": 44389,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5162,
      "choices": [
        {
          "id": 20621,
          "text": "<p><span style=\"font-size:12.0pt;\">Widal test</span></p>"
        },
        {
          "id": 20622,
          "text": "<p><span style=\"font-size:12.0pt;\">Microscopic agglutination test</span></p>"
        },
        {
          "id": 20623,
          "text": "<p><span style=\"font-size:12.0pt;\">Weil felix reaction</span></p>"
        },
        {
          "id": 20624,
          "text": "<p><span style=\"font-size:12.0pt;\">Paul Bunnell test</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 16-year-old boy is admitted with fever, icterus, conjunctival suffusion, and hematuria for 15 days. Which serological test should be done for diagnosis?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2019)</span></p>",
      "unique_key": "Q2403309",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137132,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Microscopic agglutination test</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">History of fever with liver and kidney involvement should arouse suspicion for leptospirosis (Weil's disease).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A microscopic agglutination test is used for the diagnosis of leptospirosis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Serotype-specific tests:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Microscopic agglutination test</span></li><li><span style=\"font-size:12.0pt;\">Macroscopic agglutination test</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;A. Widal test:</strong> Incorrect, the Widal test is used to diagnose typhoid fever, which involves testing for antibodies against Salmonella typhi antigens but does not present with the same symptom profile as described.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Weil Felix reaction:</strong> Incorrect, this test is historically used for diagnosing rickettsial infections, which are caused by different organisms and have different clinical features.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Paul Bunnell test (monospot test):</strong> Incorrect, this test is used to diagnose infectious mononucleosis caused by the Epstein-Barr virus, characterized by symptoms like fever, sore throat, and swollen lymph nodes but not typically associated with icterus or hematuria.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">&nbsp;The Microscopic Agglutination Test (MAT) is crucial for diagnosing leptospirosis in patients presenting with symptoms like fever, jaundice, red eyes, and hematuria, as it accurately detects the presence of antibodies against Leptospira, confirming the infection.</span></p>",
      "correct_choice_id": 20622,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2158,
      "choices": [
        {
          "id": 8621,
          "text": "<p><span style=\"font-size:12.0pt;\">Thiamine</span></p>"
        },
        {
          "id": 8622,
          "text": "<p><span style=\"font-size:12.0pt;\">Niacin</span></p>"
        },
        {
          "id": 8623,
          "text": "<p><span style=\"font-size:12.0pt;\">Pyridoxal Phosphate</span></p>"
        },
        {
          "id": 8624,
          "text": "<p><span style=\"font-size:12.0pt;\">Biotin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which among the following serves as cofactor for Glycogen phosphorylase? (AIIMS NOV 2017)</span></p>",
      "unique_key": "Q3598367",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137133,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Pyridoxal Phosphate</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Glycogen phosphorylase removes glucose as glucose- 1-phosphate from glycogen</strong> (phosphorolysis). It <strong>contains pyridoxal phosphate (PLP)</strong> as a prosthetic group. The alpha-1, 4 linkages in the glycogen are cleaved.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">PLP also acts as the coenzyme for many enzymes involved in</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Amino acid metabolism, especially <strong>transamination and decarboxylation</strong></span></li><li><span style=\"font-size:12.0pt;\"><strong>Heme</strong> synthesis</span></li><li><span style=\"font-size:12.0pt;\">Production of <strong>niacin.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.</strong> <strong>Thiamine</strong>: Thiamine is a cofactor for enzymes involved in carbohydrate metabolism, such as pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, but it is not a cofactor for glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Niacin</strong>: Niacin is a precursor for NAD and NADP, which are important cofactors in redox reactions, but it does not serve as a cofactor for glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Biotin</strong>: Biotin is a cofactor for carboxylation reactions, such as those catalyzed by pyruvate carboxylase, acetyl-CoA carboxylase, and propionyl-CoA carboxylase, but it is not involved with glycogen phosphorylase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Pyridoxal phosphate (PLP) is the cofactor for glycogen phosphorylase and is also involved in amino acid metabolism, heme synthesis, and niacin production.</span></p>",
      "correct_choice_id": 8623,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16079,
      "choices": [
        {
          "id": 64276,
          "text": "<p><span style=\"font-size:12.0pt;\">1,2,3,4,5&nbsp; &nbsp;</span></p>"
        },
        {
          "id": 64277,
          "text": "<p><span style=\"font-size:12.0pt;\">5,4,2,3,1</span></p>"
        },
        {
          "id": 64278,
          "text": "<p><span style=\"font-size:12.0pt;\">5,1,2,3,4</span></p>"
        },
        {
          "id": 64279,
          "text": "<p><span style=\"font-size:12.0pt;\">1,3,4,2,5</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Arrange in sequence the structures involved in the direct pathway: (INICET NOV 2022)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">1. Striatum</span></p><p><span style=\"font-size:12.0pt;\">2. Globus pallidus</span></p><p><span style=\"font-size:12.0pt;\">3. Substantia nigra</span></p><p><span style=\"font-size:12.0pt;\">4. Thalamus</span></p><p><span style=\"font-size:12.0pt;\">5. Cortex</span><br>&nbsp;</p>",
      "unique_key": "Q5749473",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137134,
      "difficulty_level": "difficult",
      "subjects_id": [
        3
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. 5,1,2,3,4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>The correct sequence is as follows:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>5. Cortex -</strong> provides the initial input to the basal ganglia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>1. Striatum </strong>- receives input from the cortex and is the first structure in the basal ganglia circuitry.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>2. Globus pallidus </strong>- receives inhibitory input from the striatum and projects to the thalamus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>3. Substantia nigra -</strong> provides dopaminergic input to the striatum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>4. Thalamus -</strong> receives excitatory input from the globus pallidus and projects back to the cortex to complete the loop.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The basal ganglia needs the input from the cortex in order to act. The first and last component of the pathway is always the cerebral cortex.&nbsp;</span></p><p><br><span style=\"font-size:12.0pt;\">The complete pathway is Cortex/ Thalamus/ brain stem to stratum, then to globus pallidus &amp; substantia nigra then to thalamus and then back to cortex.</span></p><p><br><span style=\"font-size:12.0pt;\">Hence out of the available options 5,1,2,3,4 is the best suitable.</span></p><p>&nbsp;</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/18/anatomy-nov-inicet-2022-01.jpg\" alt=\"\" width=\"600\" height=\"527\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The putamen is located laterally and the internal capsule is located medially to the pallidum. The striatum and subthalamic nuclei send fibres to it. It is the primary basal ganglia output to the thalamus and superior colliculus. Each cerebral peduncle of the midbrain located deep to the crus cerebri contains the substantia nigra. Dopamine levels in the substantia nigra and striata are reduced in Parkinson's disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:#0d0d0d;font-size:11.0pt;\">The correct order of structures in the direct pathway of the basal ganglia starts with the cortex and follows through the striatum, globus pallidus, substantia nigra, and ends at the thalamus. This pathway is fundamental in processing motor signals, which is particularly relevant in understanding disorders like Parkinson’s disease.</span></p>",
      "correct_choice_id": 64278,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56328,
      "choices": [
        {
          "id": 224725,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diphenhydramine</span></span></span></p>"
        },
        {
          "id": 224726,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epinephrine</span></span></span></p>"
        },
        {
          "id": 224727,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methylprednisolone</span></span></span></p>"
        },
        {
          "id": 224728,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albuterol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old woman with no significant past medical history is brought to the emergency department after accidentally ingesting a peanut-containing snack. She develops sudden-onset shortness of breath, hives, and swelling of her lips and tongue. On examination, she is in respiratory distress with low blood pressure, wheezing, and a weak pulse. The clinical team recognizes these signs as anaphylactic shock. Immediate treatment is initiated to stabilize her condition. Which of the following medications is the drug of choice for managing anaphylactic shock?</span></span></span></p>",
      "unique_key": "Q1165498",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137215,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Epinephrine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epinephrine is the first-line treatment for anaphylactic shock due to its rapid action on multiple receptors. It acts on alpha-1 receptors to cause vasoconstriction, thereby increasing blood pressure and reducing edema. Its beta-1 agonist effect enhances cardiac output, while its beta-2 agonist action leads to bronchodilation, improving respiratory function. Administered intramuscularly, epinephrine is effective in reversing the life-threatening symptoms of anaphylaxis quickly and is essential for stabilizing the patient&rsquo;s condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Diphenhydramine</span></strong><span style=\"font-size:12.0pt\">: Diphenhydramine is an antihistamine that helps alleviate allergic symptoms such as itching and hives, but it does not reverse the airway obstruction or shock associated with anaphylaxis. It is used as adjunctive therapy, not as a primary treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Methylprednisolone</span></strong><span style=\"font-size:12.0pt\">: Methylprednisolone is a corticosteroid that helps reduce inflammation and prevent delayed reactions, but its onset of action is too slow to manage the acute life-threatening symptoms of anaphylactic shock. It is used as part of long-term management rather than immediate treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Albuterol</span></strong><span style=\"font-size:12.0pt\">: Albuterol is a beta-2 agonist used for bronchodilation in asthma and other reactive airway diseases. While it can help relieve bronchospasm, it does not address the cardiovascular effects of anaphylactic shock and is not sufficient as a standalone treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Epinephrine is the drug of choice for anaphylactic shock due to its rapid action on alpha and beta receptors, which reverses vasodilation, bronchoconstriction, and cardiovascular collapse. Early administration is critical in anaphylaxis management to prevent severe complications and stabilize the patient&rsquo;s condition.</span></span></span></p>",
      "correct_choice_id": 224726,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9772,
      "choices": [
        {
          "id": 39055,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Herpes virus</span></span></span></p>"
        },
        {
          "id": 39056,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Verruca vulgaris</span></span></span></p>"
        },
        {
          "id": 39057,
          "text": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Molluscum contagiosum</span></span></span></p>"
        },
        {
          "id": 39058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lichen planus</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old male with skin-colored umbilicated papules. Microscopy is as shown below. The most likely diagnosis is: </span></span>(AIIMS MAY 2019)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/922.jpg\" style=\"height:226px; width:300px\" /></span></span></p>",
      "unique_key": "Q8423014",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137236,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Molluscum contagiosum</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The given picture shows intracytoplasmic molluscum bodies (staining purple-pink) within the keratinocytes.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Molluscum contagiosum is a common self-limiting contagious lesion caused by a poxvirus which is a DNA virus. It is more common in children and young adults. Infection is acquired by direct contact. Clinically, the lesions are often multiple, discrete, waxy, papules, about 5 mm in diameter and are seen more frequently on the face and trunk</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tzanck smear shows intracytoplasmic molluscum bodies (<strong>Henderson-Patterson bodies), the largest known inclusion bodies (30-35 m).</strong></span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/923.jpg\" style=\"height:332px; width:417px\" /></strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Individual lesions are firm, pruritic, pink to skin-colored <strong>umbilicated papules</strong> (shown below). A curd-like material can be expressed from the central umbilication</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/924.jpg\" style=\"height:312px; width:400px\" /></span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Herpes virus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Herpes simplex virus (HSV) infections typically present with grouped vesicles on an erythematous base, which then progress to pustules, ulcers, and crusts. The histology usually shows multinucleated giant cells with intranuclear inclusions on a Tzanck smear, not the intracytoplasmic molluscum bodies seen in this case.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Verruca vulgaris</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Also known as common warts, verruca vulgaris is caused by the human papillomavirus (HPV). These lesions are typically hyperkeratotic, exophytic papules with a rough surface. Histologically, they show papillomatosis, hyperkeratosis, and koilocytosis (vacuolated cells with a halo around the nucleus). These features are distinct from the molluscum bodies seen in Molluscum contagiosum.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Lichen planus</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Lichen planus is an inflammatory condition that presents with pruritic, polygonal, flat-topped, violaceous papules, often with Wickham striae (fine white lines) on the surface. Histologically, it shows a band-like lymphocytic infiltrate at the dermoepidermal junction, hypergranulosis, and saw-toothing of the rete ridges. These findings are not consistent with the histological image provided, which shows molluscum bodies.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Molluscum contagiosum is characterized by the presence of intracytoplasmic<strong> </strong>molluscum bodies (Henderson-Patterson bodies) within keratinocytes, and it presents clinically as skin-colored, umbilicated papules.</span></span></span></p>\r\n\r\n<p style=\"margin-right:3px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:3px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Robbins and Cotran pathologic basis of disease, 8<sup>th</sup> edition, Pg 1940</span></strong></span></span></p>",
      "correct_choice_id": 39057,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11091,
      "choices": [
        {
          "id": 44330,
          "text": "<p><span style=\"font-size:18px;\">Only 1</span></p>"
        },
        {
          "id": 44331,
          "text": "<p><span style=\"font-size:18px;\">1 and 2</span></p>"
        },
        {
          "id": 44332,
          "text": "<p><span style=\"font-size:18px;\">1, 2, and 3</span></p>"
        },
        {
          "id": 44333,
          "text": "<p><span style=\"font-size:18px;\">1, 2, 3, and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:18px;\"><strong>Which of the following statements accurately describe the operation and management of Mobile Medical Units (MMUs)? [</strong><i><strong>INICET MAY 2021]</strong></i></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\"><strong>MMUs are run by the government</strong></span></li><li><span style=\"font-size:18px;\"><strong>MMUs are run by external agencies with medical supplies given by the government.</strong></span></li><li><span style=\"font-size:18px;\"><strong>MMUs are run by the government and medical supplies are also given by the government.</strong></span></li><li><span style=\"font-size:18px;\"><strong>MMUs are run by external agencies and medical supplies are also given by the external agency.</strong></span></li></ol>",
      "unique_key": "Q2160858",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137237,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:18px;\"><strong>Ans. (c) 1, 2, and 3</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">MMUs can be operated by either the Government or an external agency; however, the availability of drugs and medical supplies is exclusively the responsibility of the Government.</span></li><li><span style=\"font-size:18px;\">Mobile Medical Units (MMU) represents a significant project within NRHM, aimed at delivering a variety of healthcare services to individuals residing in distant, hard-to-reach, unserved, and underserved regions, encompassing both rural and urban locations.</span></li><li><span style=\"font-size:18px;\">The goal is to bring essential healthcare services directly to the residents in these areas.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>There are 3 models of operationalizing MMUs:</strong></span></p><p>&nbsp;</p><ol><li><span style=\"font-size:18px;\">Government operated MMU</span></li><li><span style=\"font-size:18px;\">MMU operation is outsourced to an external agency, while the government covers capital expenses, medication, and supplies.</span></li><li><span style=\"font-size:18px;\">External agency outsourcing includes both capital and operational expenses for MMUs.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:18px;\">The government is responsible for providing medication and supplies. MMUs offer essential primary healthcare services for prevalent illnesses (both communicable and non-communicable), reproductive and child health (RCH) services, screening examinations, and necessary referrals to advanced facilities and specialists. Medical Officer-led clinical services are delivered by a team, while mobilization and outreach activities are undertaken by ANMs and ASHA personnel.</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><strong>Services and Resources of MMUs:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:18px;\">MMUs offer a variety of services, including primary care for common diseases, reproductive and child health services, diagnostic screenings, and referrals to specialized care.</span></li><li><span style=\"font-size:18px;\">They are equipped with facilities for basic diagnostic tests such as blood glucose monitoring, pregnancy testing, and sputum sample collection, among others.</span></li><li><span style=\"font-size:18px;\">Human resources typically include a medical officer, a nurse, a lab technician, a pharmacist/administrative assistant, and a driver/support staff.</span></li></ul>",
      "correct_choice_id": 44332,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5027,
      "choices": [
        {
          "id": 20082,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta-Glucocerebroside</span></p>"
        },
        {
          "id": 20083,
          "text": "<p><span style=\"font-size:12.0pt;\">Sphingomyelinase</span></p>"
        },
        {
          "id": 20084,
          "text": "<p><span style=\"font-size:12.0pt;\">Hexosaminidase</span></p>"
        },
        {
          "id": 20085,
          "text": "<p><span style=\"font-size:12.0pt;\">G-6-phosphatase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The following histological image is seen in the patient who is complaining of growth failure and abdominal distension.&nbsp; Signs found were anemia, thrombocytopenia and bony pain. Which enzyme is deficient in this patient? (NEET PG 2022)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/05/picture10.jpg\" alt=\"\" width=\"300\" height=\"226\"></span></p>",
      "unique_key": "Q1668353",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137238,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Beta-Glucocerebroside</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image shows a crumpled tissue paper appearance of cell which is a characteristic feature of Gaucher’s disease. It is a sphingolipidoses and the most common lysosomal storage disease and occur due to deficiency of lysosomal enzyme β-glucocerebrosidase. The substrate glucosylceramide gets accumulated in macrophages causing eccentric nucleus.</span></p><p><span style=\"font-size:12.0pt;\">Other clinical features are: Bony pain, pathological fracture, hepatosplenomegaly but no mental retardation (as beta-glucosylceramide is not present in brain).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Sphingomyelinase:&nbsp;</strong>Deficiency of this enzyme leads to Niemann-Pick disease, characterized by the accumulation of sphingomyelin in macrophages. Clinical features include hepatosplenomegaly, progressive neurodegeneration, and the presence of foam cells. Niemann-Pick disease often presents with mental retardation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C. Hexosaminidase:&nbsp;</strong>This enzyme has two forms, A and B. Deficiency of Hexosaminidase A leads to Tay-Sachs disease, characterized by the accumulation of GM2 ganglioside, primarily affecting neurons. Clinical features include progressive neurodegeneration, a cherry-red spot on the macula, and early death. Deficiency of both Hexosaminidase A and B leads to Sandhoff disease, which presents similarly to Tay-Sachs but with additional visceral involvement.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. G-6-phosphatase:&nbsp;</strong>Deficiency of this enzyme leads to Von Gierke’s disease (Glycogen Storage Disease Type I), characterized by impaired glycogenolysis and gluconeogenesis. Clinical features include severe hypoglycemia, lactic acidosis, hepatomegaly, hyperlipidemia, and hyperuricemia. Patients often present with a doll-like facies, protuberant abdomen, and growth retardation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Gaucher’s Disease</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/03/screenshot-2024-06-03-162124.jpg\" alt=\"\" width=\"1000\" height=\"523\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/03/screenshot-2024-06-03-162347.jpg\" alt=\"\" width=\"1000\" height=\"443\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: Harper’s 31<sup>st</sup> ed/pg- 235</strong></span></p>",
      "correct_choice_id": 20082,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31811,
      "choices": [
        {
          "id": 127114,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Oprelvekin </span></span></p>"
        },
        {
          "id": 127115,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib </span></span></p>"
        },
        {
          "id": 127116,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Eltrombopag </span></span></p>"
        },
        {
          "id": 127117,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bosutinib</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient presents with widespread purpura and easy bruising. Laboratory tests reveal a significantly low platelet count with normal hemoglobin and white blood cell count, indicating a diagnosis of isolated thrombocytopenia. The patient has no prior history of autoimmune disorders or recent viral infections. Considering these symptoms and diagnosis, which tyrosine kinase inhibitor would be appropriate for this patient? (INICET NOV 2023)</span></span></p>",
      "unique_key": "Q8292950",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137239,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans B) Fostamatinib.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib is the suitable choice in this case. It is a tyrosine kinase inhibitor used specifically for the treatment of chronic immune thrombocytopenia (ITP), a condition characterized by isolated thrombocytopenia, which manifests as low platelet counts leading to symptoms like purpura and easy bruising. It operates by inhibiting spleen tyrosine kinase (Syk), thereby reducing the destruction of platelets and helping to increase the platelet count.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Oprelvekin:</strong> Oprelvekin is not a tyrosine kinase inhibitor; it is a thrombopoietic growth factor used to increase platelet production, particularly in cases of chemotherapy-induced thrombocytopenia, rather than isolated thrombocytopenia without a clear underlying cause.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Eltrombopag:</strong> Eltrombopag is a thrombopoietin receptor agonist, not a tyrosine kinase inhibitor. It is used to treat thrombocytopenia, including ITP, but through a different mechanism - stimulating platelet production in the bone marrow.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Bosutinib:</strong> Bosutinib is a tyrosine kinase inhibitor; however, its primary use is in treating chronic myelogenous leukemia (CML), not isolated thrombocytopenia or ITP. It targets the BCR-ABL tyrosine kinase, which is not involved in the pathology of ITP.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib is a tyrosine kinase inhibitor specifically used for treating chronic immune thrombocytopenia (ITP) by inhibiting spleen tyrosine kinase (Syk) to reduce platelet destruction and increase platelet count.</span></span></p>",
      "correct_choice_id": 127115,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6506,
      "choices": [
        {
          "id": 25993,
          "text": "<p><span style=\"font-size:12.0pt;\">Premature closure of ductus arteriosus</span></p>"
        },
        {
          "id": 25994,
          "text": "<p><span style=\"font-size:12.0pt;\">Keeps ductus arteriosus patent</span></p>"
        },
        {
          "id": 25995,
          "text": "<p><span style=\"font-size:12.0pt;\">Closure of fossa ovalis</span></p>"
        },
        {
          "id": 25996,
          "text": "<p><span style=\"font-size:12.0pt;\">Premature closure of ductus venous</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant woman was prescribed indomethacin. Which of the following effects does the drug have on the fetus? (NEET PG 2021)</span></p>",
      "unique_key": "Q1635598",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137240,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A)</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Premature closure of ductus arteriosus</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Indomethacin is an NSAID, that acts by inhibiting the Cyclooxygenase (COX) enzyme, thereby decreasing the synthesis of Prostaglandins. Prostaglandins are necessary for maintaining the patency of the ductus arteriosus in the fetus. Therefore, Indomethacin if given to a pregnant woman can lead to premature closure of the ductus arteriosus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Keeps ductus arteriosus patent</strong>: Indomethacin does not keep the ductus arteriosus patent; instead, it promotes its closure by inhibiting prostaglandin synthesis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Closure of fossa ovalis</strong>: The closure of the fossa ovalis is not influenced by indomethacin. The fossa ovalis is a different fetal structure that closes postnatally due to changes in pressure gradients.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Premature closure of ductus venous</strong>: The ductus venosus closure is not affected by indomethacin. This structure typically closes naturally after birth.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Indomethacin, an NSAID, can cause the premature closure of the ductus arteriosus in a fetus due to its inhibition of prostaglandin synthesis. Therefore, caution should be exercised when prescribing this drug to pregnant women, particularly in the third trimester.</span></p>",
      "correct_choice_id": 25993,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14145,
      "choices": [
        {
          "id": 56541,
          "text": "<p><span style=\"font-size:12.0pt;\">TACE is used for multinodular lesions</span></p>"
        },
        {
          "id": 56542,
          "text": "<p><span style=\"font-size:12.0pt;\">Lenvatinib is used for lesions less than 3 cm</span></p>"
        },
        {
          "id": 56543,
          "text": "<p><span style=\"font-size:12.0pt;\">The incidence of HCC is increasing</span></p>"
        },
        {
          "id": 56544,
          "text": "<p><span style=\"font-size:12.0pt;\">NASH and NAFLD are risk factors for HCC</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the false statement out of the following: (INICET NOV 2021)</span></p>",
      "unique_key": "Q6501288",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137241,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Lenvatinib is used for lesions less than 3 cm</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Lenvatinib is used to treat advanced stages of hepatocellular carcinoma (HCC). Treatment of lesions less than 3 cm is wide excision or liver transplant.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. TACE is used for multinodular</strong> <strong>lesions</strong>: <strong>True</strong>. TACE (Transarterial chemoembolization) combined with other treatments is used for unresectable multiple nodular and massive HCC, especially when a single nodular diameter is greater than 5 cm (intermediate or advanced HCC).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. The incidence of HCC is</strong> <strong>increasing</strong>: <strong>True</strong>. The incidence of HCC is increasing worldwide due to the increase in HCV and HBV infections, along with lifestyle disorders like obesity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D. NASH (Non-Alcoholic Steatohepatitis) and NAFLD (Non-Alcoholic Fatty Liver Disease) are risk factors for</strong> <strong>HCC</strong>: <strong>True</strong>. Obesity is associated with non-alcoholic fatty liver disease (NALD), which progresses to non-alcoholic steatohepatitis (NASH) causing cirrhosis and hepatocellular carcinoma. Thus, NASH and NAFLD are risk factors for HCC.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The Barcelona-Clinic-Liver Cancer (BCLC) Classification is the commonly used staging system for HCC.</span></li><li><span style=\"font-size:12.0pt;\">Very early HCC is treated by ablation, early HCC with a single nodule is resected, and when there are multiple nodules over 3 cm, ablation or transplantation are considered.</span></li><li><span style=\"font-size:12.0pt;\">Intermediate stage HCC is treated by chemoembolization, and TACE (Trans-arterial chemoembolization) is used for multinodular lesions.</span></li><li><span style=\"font-size:12.0pt;\">Advanced stages of the disease with macrovascular invasion are treated with systemic therapies. Lenvatinib and sorafenib are first-line drugs.</span></li><li><span style=\"font-size:12.0pt;\">Supportive care is given at the terminal stage of the disease.</span></li></ul>",
      "correct_choice_id": 56542,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56329,
      "choices": [
        {
          "id": 224729,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alendronate</span></span></span></p>"
        },
        {
          "id": 224730,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Denosumab</span></span></span>&nbsp;&nbsp;&nbsp;&nbsp;</p>"
        },
        {
          "id": 224731,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Teriparatide</span></span></span></p>"
        },
        {
          "id": 224732,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raloxifene hydrochloride</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old postmenopausal woman with a history of osteoporosis presents to her endocrinologist for follow-up. She has been on calcium and vitamin D supplementation but recently suffered a fragility fracture of her wrist. The patient expresses concern about her bone health and asks about medications that can help strengthen her bones and reduce her fracture risk. After reviewing her case, the endocrinologist decides to prescribe a medication that specifically stimulates bone formation rather than just preventing bone loss. Which of the following drugs stimulates bone formation?</span></span></span></p>",
      "unique_key": "Q7935431",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137312,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Teriparatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Teriparatide is a recombinant form of parathyroid hormone (PTH) that stimulates bone formation by activating osteoblasts more than osteoclasts when administered intermittently. Unlike other osteoporosis medications that primarily inhibit bone resorption, teriparatide promotes new bone growth, increases bone mass, and improves bone microarchitecture, significantly reducing fracture risk in patients with severe osteoporosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alendronate</span></strong><span style=\"font-size:12.0pt\">: Alendronate is a bisphosphonate that works by inhibiting osteoclast-mediated bone resorption, thereby reducing bone loss. However, it does not directly stimulate new bone formation, making it distinct from anabolic agents like teriparatide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Denosumab</span></strong><span style=\"font-size:12.0pt\">: Denosumab is a monoclonal antibody that inhibits RANK ligand, a key factor in the formation and activity of osteoclasts, thus decreasing bone resorption. It effectively prevents further bone loss but does not promote the formation of new bone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Raloxifene hydrochloride</span></strong><span style=\"font-size:12.0pt\">: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that helps reduce bone resorption by mimicking estrogen&rsquo;s protective effects on bone. It does not directly stimulate bone formation and is primarily used to prevent bone loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DRUGS USED IN OSTEOPOROSIS</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/09/screenshot-2024-09-09-095025.png\" style=\"height:562px; width:1000px\" /></p>",
      "correct_choice_id": 224731,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9878,
      "choices": [
        {
          "id": 39478,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">GATA1</span></span></span></p>"
        },
        {
          "id": 39479,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">PIT1</span></span></span></p>"
        },
        {
          "id": 39480,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">ТРІТ</span></span></span></p>"
        },
        {
          "id": 39481,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">SF1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">A patient presented to the OPD with long hands and feet, and a protruding lower jaw. Which of the following genes is most likely implicated in this scenario? </span></span></span>(INICET NOV 2020)</p>",
      "unique_key": "Q3157840",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137313,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) PIT1</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Mutations of the pituitary-specific gene <strong>PIT-1</strong> can lead to the development of a somatotroph adenoma which produces elevated levels of GH Growth hormone (and IGF-1) which can lead to <strong>acromegaly </strong>as given in the clinical scenario above.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Somatotrophs, mammosomatotrophs, and lactotrophs are derived from stem cells that express the pituitary transcription factor, PIT-1.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">If the increased levels of GH are present after closure of the epiphyses, acromegaly develops. In this condition, growth is most conspicuously seen in</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Skin and soft tissues, viscera (thyroid, heart, liver, and adrenals).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">The bones of the face, hands, and feet are thickened and enlarged.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Bone density may increase (hyperostosis) in both the spine and the hips.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Enlargement and protrusion of the jaw is seen (prognathism), and broadening of the lower face.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">The feet and hands are enlarged, and the fingers become thickened and sausage-like.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/04/screenshot-2024-09-04-181302.png\" style=\"height:561px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">GH excess can also be associated with a variety of other manifestations, like gonadal dysfunction, <strong>diabetes mellitus</strong>, generalized <strong>muscle weakness, hypertension, arthritis, congestive heart failure</strong>, and an increased risk of <strong>gastrointestinal cancers</strong>.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. GATA1:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This gene is associated with hematopoiesis and mutations in GATA1 are linked to blood disorders, not acromegaly.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. TPIT (TBX19):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This gene is involved in the development of corticotroph cells in the pituitary and is associated with ACTH production, not GH.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. SF1 (Steroidogenic factor 1):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> SF1 is important in the development of the adrenal glands and gonads, and its mutations are associated with disorders of sex development, not acromegaly.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PIT1&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">mutations are implicated in the development of somatotroph adenomas, leading to <strong>acromegaly</strong> with features such as enlarged hands, feet, and a protruding lower jaw.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref:&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Robbin and Cotran pathological basis of disease 8<sup>th</sup> edition pg 2129</span></strong></span></span></p>",
      "correct_choice_id": 39479,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16132,
      "choices": [
        {
          "id": 64488,
          "text": "<p><span style=\"font-size:12.0pt;\">Age &lt;10 years</span></p>"
        },
        {
          "id": 64489,
          "text": "<p><span style=\"font-size:12.0pt;\">PT &gt;100s</span></p>"
        },
        {
          "id": 64490,
          "text": "<p><span style=\"font-size:12.0pt;\">Bilirubin &gt;300 µmol/L&nbsp;</span></p>"
        },
        {
          "id": 64491,
          "text": "<p><span style=\"font-size:12.0pt;\">Jaundice less than 7 days before development of encephalopathy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 5-year-old child with Wilson's disease is being considered for liver transplantation. According to King's College Criteria for predicting mortality in Acute Liver Failure (ALF), which of the following is not included?</span></p>",
      "unique_key": "Q8395685",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137314,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Jaundice less than 7 days before development of encephalopathy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">King's College Criteria are widely used to predict mortality in patients with acute liver failure and identify those who may require urgent liver transplantation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Jaundice less than 7 days before development of encephalopathy: According to the King's College Criteria for non-paracetamol causes, a duration of jaundice before the onset of encephalopathy greater than 7 days (not less than 7 days) is one of the parameters that might indicate the need for liver transplantation. If the encephalopathy develops rapidly after the onset of jaundice (i.e., within 7 days), it suggests a more acute and potentially reversible cause, such as acute viral hepatitis, which might recover without transplantation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Given the information, the incorrect parameter in the King's College criteria for transplantation, would be \"Jaundice less than 7 days before development of encephalopathy\" (Option D).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/09/screenshot-2024-07-09-162420.jpg\" alt=\"\" width=\"1000\" height=\"675\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A.</strong> <strong>Age &lt;10 years:</strong> Age is a factor in the King's College Criteria for non-paracetamol-induced liver failure. Children aged less than 10 years are considered at higher risk and this age group may be included in the criteria for transplantation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B</strong>. <strong>PT &gt;100s:</strong> Prothrombin time (PT) reflects the liver's ability to synthesize clotting factors. A greatly prolonged PT (&gt;100 seconds) is an indication of severe liver dysfunction and is one of the King's College Criteria for both paracetamol and non-paracetamol-induced liver failure as a potential requirement for liver transplantation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C.</strong> <strong>Bilirubin &gt;300 µmol/L</strong>: An elevated bilirubin level indicates significant liver dysfunction. A bilirubin level greater than 300 µmol/L is one of the King's College Criteria for non-paracetamol-induced liver failure and suggests that liver transplantation may be necessary.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">King's College Criteria for liver transplantation in acute liver failure include specific parameters such as <strong>prolonged PT, elevated bilirubin, and specific age groups</strong>. The duration of jaundice before the development of encephalopathy is significant if it exceeds 7 days. Jaundice for less than 7 days is not a parameter for transplantation.</span></p>",
      "correct_choice_id": 64491,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56330,
      "choices": [
        {
          "id": 224733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced age</span></span></span></p>"
        },
        {
          "id": 224734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking</span></span></span></p>"
        },
        {
          "id": 224735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liver dysfunction</span></span></span></p>"
        },
        {
          "id": 224736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal failure</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following factors does NOT increase the risk of lactic acidosis in patients taking metformin? (AIIMS MAY 2015)</span></span></span></p>",
      "unique_key": "Q8093646",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137355,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Smoking</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking is not directly associated with an increased risk of lactic acidosis in patients using metformin. While smoking has many detrimental health effects, it does not contribute to the renal or liver dysfunction that can intensify the effects of metformin to produce lactic acidosis. Metformin-induced lactic acidosis is generally associated with conditions that impair metformin excretion or distribution within the body, such as renal failure or severe liver disease, or conditions that reduce tissue perfusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Advanced age:</span></strong><span style=\"font-size:12.0pt\"> often correlates with decreased renal function, which can impair the clearance of metformin from the body, thus increasing the risk of lactic acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liver dysfunction:</span></strong><span style=\"font-size:12.0pt\"> can alter lactate metabolism and clearance, thereby enhancing the risk of lactic acidosis when taking metformin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Renal failure:</span></strong><span style=\"font-size:12.0pt\"> significantly increases the risk because metformin is cleared by the kidneys; impaired kidney function can lead to an accumulation of the drug, which increases the likelihood of developing lactic acidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While smoking has many adverse health effects, it does not increase the risk of lactic acidosis in metformin users, unlike factors such as renal and liver dysfunction, which directly impact the metabolism and clearance of the drug.</span></span></span></p>",
      "correct_choice_id": 224734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44823,
      "choices": [
        {
          "id": 178939,
          "text": "<p><span style=\"font-size:12pt;\">Syrup Dextromethorphan with bromhexine</span></p>"
        },
        {
          "id": 178940,
          "text": "<p><span style=\"font-size:12pt;\">Syrup Codeine</span></p>"
        },
        {
          "id": 178941,
          "text": "<p><span style=\"font-size:12.0pt;\">Syrup dextromethorphan</span></p>"
        },
        {
          "id": 178942,
          "text": "<p><span style=\"font-size:12pt;\">Syrup bromhexine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">A 30-year-old patient presented with fever, cough and tenacious white sputum. Which of the following should be used for treatment? (INICET MAY 2024)</span></p>",
      "unique_key": "Q2531058",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137356,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Syrup bromhexine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Bromhexine is a mucolytic agent that helps to thin and loosen mucus, making it easier to expectorate. This is particularly useful for patients with a productive cough and tenacious sputum, as it facilitates the clearance of mucus from the airways.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;A.</strong>&nbsp;<strong>Syrup Dextromethorphan with bromhexine</strong>: Dextromethorphan is a cough suppressant, and bromhexine is a mucolytic. While bromhexine can help thin the mucus, dextromethorphan is not recommended for productive coughs as it suppresses the cough reflex, potentially leading to mucus retention.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B.</strong>&nbsp;<strong>Syrup Codeine</strong>: Codeine is an opioid cough suppressant. Like dextromethorphan, it is not suitable for productive coughs as it suppresses the cough reflex, which can lead to mucus accumulation in the airways.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C.</strong>&nbsp;<strong>Syrup Dextromethorphan</strong>: Dextromethorphan is a cough suppressant that is not appropriate for productive coughs, as it can prevent the clearing of mucus from the respiratory tract.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In summary, syrup bromhexine is the most appropriate choice for treating a patient with fever, cough, and tenacious white sputum, as it helps to thin and loosen the mucus, making it easier to clear from the respiratory tract.</span></p>",
      "correct_choice_id": 178942,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5159,
      "choices": [
        {
          "id": 20609,
          "text": "<p><span style=\"font-size:12.0pt;\">Leptospira</span></p>"
        },
        {
          "id": 20610,
          "text": "<p><span style=\"font-size:12.0pt;\">Bacillus cereus</span></p>"
        },
        {
          "id": 20611,
          "text": "<p><span style=\"font-size:12.0pt;\">Campylobacter</span></p>"
        },
        {
          "id": 20612,
          "text": "<p><span style=\"font-size:12.0pt;\">Legionella</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">BCYE medium is used to culture?</span> <span style=\"font-size:12.0pt;\">(NEET PG 2019)</span></p>",
      "unique_key": "Q2191108",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137357,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Legionella</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">BCYE medium (buffered charcoal yeast extract agar) is used to culture Legionella pneumophila.&nbsp;Legionella pneumophila has fastidious growth requirements and grows on complex media such as <u>BCYE medium with L-cysteine and antibiotic supplements</u> (e.g, polymyxin B, cefazolin, vancomycin). The charcoal acts as a detoxifying agent. It grows slowly, and the colonies may take 3-6 days to appear.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A:</strong> Leptospira is cultured on EMJH (Ellinghausen, McCullough, Johnson and Harris) medium</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B:</strong> Bacillus cereus is cultured on PEMBA (Polymyxin pyruvate egg-yolk mannitol-bromothymol blue) agar, which includes Polymyxin, pyruvate, egg yolk, mannitol, and bromothymol blue to differentiate it from other organisms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong> Campylobacter is cultured on selective media such as Skirrow's, Campy BAP or Butzler's agar.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">BCYE medium is essential for the successful isolation and culture of Legionella species, particularly Legionella pneumophila, from environmental and clinical specimens. This medium meets the specific nutritional requirements and provides a protective environment for the growth of this pathogen.</span></p>",
      "correct_choice_id": 20612,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13998,
      "choices": [
        {
          "id": 55953,
          "text": "<p><span style=\"font-size:12.0pt;\">Pericardial Effusion</span></p>"
        },
        {
          "id": 55954,
          "text": "<p><span style=\"font-size:12.0pt;\">Pneumothorax</span></p>"
        },
        {
          "id": 55955,
          "text": "<p><span style=\"font-size:12.0pt;\">Retroperitoneal hematoma</span></p>"
        },
        {
          "id": 55956,
          "text": "<p><span style=\"font-size:12.0pt;\">Renal injury</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old male arrives at the emergency department following a motor vehicle accident. The patient's vital signs are stable, and a focused assessment with sonography for trauma (FAST) is ordered. Which condition is least likely to be diagnosed using FAST? (AIIMS MAY 2020)</span></p>",
      "unique_key": "Q3298411",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137358,
      "difficulty_level": "beginner",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Retroperitoneal hematoma</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Detecting retroperitoneal hematoma is challenging with FAST because it is located deep within the abdominal cavity, behind the peritoneum. FAST primarily focuses on the pericardium, pleura, and peritoneum, making it less suitable for detecting retroperitoneal injuries.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Pericardial</strong> <strong>Effusion</strong>: FAST is effective at detecting pericardial effusions. It involves examining the pericardial sac for fluid accumulation with probe placed in epigastrium.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Pneumothorax</strong>: eFAST can detect pneumothorax to some extent by visualizing the pleural space for the presence of air.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Renal</strong> <strong>Injury</strong>: FAST can detect renal injuries by examining the perinephric space for signs of bleeding or fluid accumulation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Among the given options, FAST is the least effective in diagnosing retroperitoneal hematoma due to poor sensitivity of ultrasound for detecting it.</span></li><li><span style=\"font-size:12.0pt;\">CT scan is the preferred diagnostic tool for retroperitoneal injuries, but it should only be performed on hemodynamically stable patients.</span></li><li><span style=\"font-size:12.0pt;\">FAST stands for Focussed Assessment with Sonography for Trauma and is a non-invasive, rapid bedside test used to detect free fluid in the abdomen using sonography.</span></li><li><span style=\"font-size:12.0pt;\">The patient is positioned supine, and a 3.5-5.0 MHz convex transducer is used to scan the subxiphoid, right and left upper quadrants, and suprapubic region to assess potential thoracoabdominal injuries.</span></li><li><span style=\"font-size:12.0pt;\">eFAST is an extended version of FAST that incorporates left and right thoracic views to assess for pneumothorax and hemothorax.</span></li></ul>",
      "correct_choice_id": 55955,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24392,
      "choices": [
        {
          "id": 97529,
          "text": "<p><span style=\"font-size:12.0pt;\">Cotard's syndrome</span></p>"
        },
        {
          "id": 97530,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypochondriacal delusion</span></p>"
        },
        {
          "id": 97531,
          "text": "<p><span style=\"font-size:12.0pt;\">Nihilistic delusion</span></p>"
        },
        {
          "id": 97532,
          "text": "<p><span style=\"font-size:12.0pt;\">Bizarre delusion</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In this case, a young boy is exhibiting symptoms of reduced mood, decreased energy, and diminished engagement with his environment. He has refrained from eating for the past week and his thoughts include phrases like \"I have lost my mind. I am deceased. How can I consume food?\". What is the specific delusion in this scenario?&nbsp;</span>(INICET MAY 2023)</p>",
      "unique_key": "Q8156509",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137359,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Nihilistic delusion</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Nihilistic delusion (delusion of negation, Cotard syndrome): Patients may deny the existence of their body, their mind, or the world in general. For example, a patient with severe depression claimed that all his internal organs have rotted.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Here, the best answer is Nihilistic delusion rather than Cotard syndrome because the question has specifically asked the type of delusion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B.&nbsp;Hypochondriacal delusion: </strong>Hypochondriacal delusion&nbsp;is an illness anxiety disorder. It is characterized by a preoccupation with having or acquiring a serious physical illness. The preoccupation persists despite normal investigations and medical reassurances.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D.&nbsp;Bizarre delusion</strong>:</span> <span style=\"font-size:12.0pt;\">Scientifically impossible and culturally implausible (un-understandable). For example, a patient claimed that aliens stole his heart and lungs, and now he is living without those organs.</span></p>",
      "correct_choice_id": 97531,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6484,
      "choices": [
        {
          "id": 25905,
          "text": "<p><span style=\"font-size:12.0pt;\">Erythromycin</span></p>"
        },
        {
          "id": 25906,
          "text": "<p><span style=\"font-size:12.0pt;\">Cefotaxime</span></p>"
        },
        {
          "id": 25907,
          "text": "<p><span style=\"font-size:12.0pt;\">Cotrimoxazole</span></p>"
        },
        {
          "id": 25908,
          "text": "<p><span style=\"font-size:12.0pt;\">Amoxicillin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old female patient with a history of chronic obstructive pulmonary disease (COPD) has been taking theophylline for bronchodilation. She now presents with a respiratory infection, and the physician is considering antibiotic therapy. Which of the following antibiotics should not be prescribed with theophylline? (NEET PG 2020)</span></p>",
      "unique_key": "Q4059398",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137360,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Erythromycin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Erythromycin is known to inhibit the metabolism of theophylline, resulting in elevated blood levels of theophylline. This increases the risk of theophylline toxicity, which can lead to symptoms like nausea, vomiting, seizures, and even cardiac arrhythmias.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Cefotaxime:</strong> Cefotaxime is a cephalosporin antibiotic and is generally not known to interact significantly with theophylline. It is a safer choice compared to erythromycin in patients on theophylline therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Cotrimoxazole:</strong> Cotrimoxazole is a combination of trimethoprim and sulfamethoxazole and is not known to have a significant interaction with theophylline. It can be used safely in patients taking theophylline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Amoxicillin:</strong> Amoxicillin is a penicillin antibiotic and does not have significant interactions with theophylline. It can be safely co-prescribed with theophylline.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Erythromycin should not be prescribed with theophylline because it inhibits the metabolism of theophylline, leading to elevated blood levels and an increased risk of toxicity.</span></p>",
      "correct_choice_id": 25905,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10310,
      "choices": [
        {
          "id": 41206,
          "text": "<p><span style=\"font-size:12.0pt;\">About 20-30% of the infections are symptomatic</span></p>"
        },
        {
          "id": 41207,
          "text": "<p><span style=\"font-size:12.0pt;\">Triad of SNHL, periventricular calcification and enamel hypoplasia</span></p>"
        },
        {
          "id": 41208,
          "text": "<p><span style=\"font-size:12.0pt;\">Most children asymptomatic at birth can develop conductive hearing loss later in life</span></p>"
        },
        {
          "id": 41209,
          "text": "<p><span style=\"font-size:12.0pt;\">If mother is IgG positive for CMV, the child is unlikely to develop infection</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a true statement about congenital CMV infection? (INICET MAY 2021)</span></p>",
      "unique_key": "Q3988594",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137361,
      "difficulty_level": "intermediate",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) If mother is IgG positive for CMV, the child is unlikely to develop infection</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Congenital cytomegalovirus (CMV) infection is a significant cause of congenital infection and can lead to a range of outcomes in the fetus, depending on the timing and nature of maternal infection. If a mother is IgG positive for CMV, it indicates a past infection and a lower risk of transmitting the virus to the fetus compared to a primary infection. This is because maternal IgG antibodies can provide some protection to the fetus. However, there remains a small risk of reactivation of the virus or reinfection during pregnancy, which could lead to congenital CMV infection in the fetus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. About 20-30% of the infections are symptomatic:&nbsp;</strong>About 20-30% of the infections are symptomatic is incorrect because the correct percentage of symptomatic congenital CMV infections at birth is about 10%, not 20-30%.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Triad of SNHL, periventricular calcification and enamel hypoplasia</strong>: Triad of SNHL, periventricular calcification and enamel hypoplasia is incorrect because enamel hypoplasia is not a typical part of the triad for congenital CMV infection. The common findings include SNHL, periventricular calcifications, and developmental delays.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Most children asymptomatic at birth can develop conductive hearing loss later in life</strong>: Most children asymptomatic at birth can develop conductive hearing loss later in life is incorrect because asymptomatic infants at birth are less likely to develop hearing loss, and if they do, it is usually sensorineural, not conductive.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Maternal IgG positivity for CMV suggests a lower risk of congenital CMV transmission, making it less likely for the fetus to develop the infection.</span></p>",
      "correct_choice_id": 41209,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11696,
      "choices": [
        {
          "id": 46750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">First degree of heart block</span></span></span></span></p>"
        },
        {
          "id": 46751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AR</span></span></span></span></p>"
        },
        {
          "id": 46752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcified valve</span></span></span></span></p>"
        },
        {
          "id": 46753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mild MS</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Disappearance of loud S1 in mitral stenosis occurs in all except: (AIIMS NOV 2018)</span></span></span></span></p>",
      "unique_key": "Q5302971",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137362,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Mild MS. </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loud S1 can be heard in mild MS also because loud S1 does not depend on severity of MS. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Loud S1 is one of the auscultatory hallmarks of MS, however it can be attenuated in a variety of conditions: </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Associated MR</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long PR (first degree heart block)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CCF</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe AR- regurgitant jet may impinge on AML</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcified valve </span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. First degree heart block:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Here, the prolonged PR interval delays the closure of the mitral valve relative to ventricular contraction, often softening or eliminating the loud S1.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. AR (Aortic Regurgitation):&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The regurgitant flow in aortic regurgitation can prevent the mitral valve leaflets from closing tightly and sharply, thus softening the S1.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Calcified valve:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcification of the mitral valve leads to stiffening of the leaflets, which inhibits their rapid movement and thus reduces the intensity of S1.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In mitral stenosis, a loud S1 is typically present unless there is an associated condition that affects the mobility or timing of the mitral valve leaflet closure, such as calcification, regurgitation in other valves, or disturbances in electrical conduction that affect heart rhythm</span></span></span></span></p>",
      "correct_choice_id": 46753,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56331,
      "choices": [
        {
          "id": 224737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amoxicillin trihydrate</span></span></span></p>"
        },
        {
          "id": 224738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azithromycin</span></span></span></p>"
        },
        {
          "id": 224739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ciprofloxacin</span></span></span></p>"
        },
        {
          "id": 224740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxycycline</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old man with a history of asthma presents to the clinic with fever, sore throat, and mild respiratory distress. He is diagnosed with a bacterial throat infection and is prescribed an antibiotic. Two days after starting the medication, he develops a widespread maculopapular rash on his trunk and limbs, which is mildly pruritic but without other systemic symptoms. He has no known drug allergies, and his asthma is well-controlled with inhalers. Which of the following antibiotics is most likely responsible for this adverse reaction?</span></span></span></p>",
      "unique_key": "Q2541650",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137574,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Amoxicillin trihydrate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amoxicillin trihydrate is commonly associated with the development of a maculopapular rash, especially in patients with viral infections such as Epstein-Barr virus (EBV) or in those with asthma or other allergic conditions. This rash is typically non-itchy, appears a few days after starting the medication, and is not usually indicative of a true allergic reaction but rather a drug-related hypersensitivity reaction. In asthmatic patients, the predisposition to allergic and hypersensitivity reactions makes amoxicillin trihydrate a likely cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Azithromycin</span></strong><span style=\"font-size:12.0pt\">: Azithromycin is a macrolide antibiotic that is less commonly associated with hypersensitivity reactions compared to beta-lactam antibiotics like amoxicillin trihydrate. Maculopapular rashes are rare with azithromycin, and it is generally well tolerated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ciprofloxacin</span></strong><span style=\"font-size:12.0pt\">: Ciprofloxacin, a fluoroquinolone, can cause various side effects, including gastrointestinal disturbances and tendonitis, but maculopapular rashes are not commonly seen as a reaction. It is unlikely to be the cause in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Doxycycline</span></strong><span style=\"font-size:12.0pt\">: Doxycycline, a tetracycline antibiotic, can cause photosensitivity and gastrointestinal side effects but is not commonly associated with maculopapular rashes. It is less likely to cause such a reaction compared to amoxicillin trihydrate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amoxicillin trihydrate can frequently cause maculopapular rashes, particularly in patients with underlying viral infections, asthma, or allergic conditions. Recognizing drug-specific hypersensitivity reactions helps guide clinical decisions in managing antibiotic therapy and avoiding unnecessary discontinuation or mislabeling of drug allergies.</span></span></span></p>",
      "correct_choice_id": 224737,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14354,
      "choices": [
        {
          "id": 57377,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension + Tachycardia </span></span></span></p>"
        },
        {
          "id": 57378,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension + Tachycardia </span></span></span></p>"
        },
        {
          "id": 57379,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypotension + Bradycardia </span></span></span></p>"
        },
        {
          "id": 57380,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertension + Bradycardia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How is neurogenic shock characterized? (INICET MAY 2022)</span></span></p>",
      "unique_key": "Q4984898",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137645,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Hypotension + Bradycardia.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurogenic shock is characterized by hypotension (low blood pressure) and bradycardia (slow heart rate). This condition is a result of the disruption of the sympathetic nervous system, which often occurs due to a spinal cord injury, particularly affecting the cervical or high thoracic regions. The loss of sympathetic tone leads to unopposed parasympathetic activity, causing widespread vasodilation, decreased systemic vascular resistance, and reduced heart rate, all contributing to decreased cardiac output and blood pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypertension + Tachycardia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This combination is not typical of neurogenic shock; it is more likely seen in conditions involving excess sympathetic activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hypotension + Tachycardia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is more typical of other forms of shock, such as hemorrhagic or septic, where compensatory mechanisms increase heart rate to maintain cardiac output despite low blood volume or vasodilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypertension + Bradycardia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This combination is also incorrect for neurogenic shock. It could be seen in other medical scenarios, such as intracranial pressure increases, but not typically in shock states.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neurogenic shock should be recognized by its key characteristics of hypotension and bradycardia, resulting from a loss of sympathetic tone and unopposed parasympathetic activity due to spinal cord injury.</span></span></span></p>",
      "correct_choice_id": 57379,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7159,
      "choices": [
        {
          "id": 28604,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raltegravir</span></span></span></span></span></p>"
        },
        {
          "id": 28605,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Enfuvirtide</span></span></span></span></span></p>"
        },
        {
          "id": 28606,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Tenofovir</span></span></span></span></span></p>"
        },
        {
          "id": 28607,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Zidovudine</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image below shows the life cycle of human immunodeficiency virus. Which of the following drugs acts at step 5? (INICET NOV 2022)</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/752.jpg\" style=\"height:262px; width:300px\" /></span></span></span></span></span></p>",
      "unique_key": "Q1043661",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137646,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A.&nbsp;</span></span></strong></span><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raltegravir</span></span></strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The step 5 in the given image shows the step of integration of the viral genome into the host DNA with the help of Integrase enzyme. Among the above given drugs, Raltegravir can be used to block this step as it is an integrase inhibitor.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/8.jpg\" style=\"height:491px; width:600px\" /></span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Enfuvirtide:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is fusion inhibitor, which acts by binding to gp41 protein on the surface of the virus. This inhibits the Step 1 of this diagram.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tenofovir &amp; Option D) Zidovudine</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: These are NRTIs which are used in combination therapy against HIV virus. NRTI works by inhibiting the activity of reverse transcriptase (Step 6 of the diagram), thereby, preventing the viral replication.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 28604,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6468,
      "choices": [
        {
          "id": 25841,
          "text": "<p><span style=\"font-size:12.0pt;\">Dinoprost</span></p>"
        },
        {
          "id": 25842,
          "text": "<p><span style=\"font-size:12.0pt;\">Dinoprostone</span></p>"
        },
        {
          "id": 25843,
          "text": "<p><span style=\"font-size:12.0pt;\">Misoprostol</span></p>"
        },
        {
          "id": 25844,
          "text": "<p><span style=\"font-size:12.0pt;\">Carboprost</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is a synthetic PGE1 derivative used as an abortifacient? (NEET PG 2019)</span></p>",
      "unique_key": "Q6493422",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137647,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Misoprostol</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Misoprostol is a synthetic prostaglandin E1 (PGE1) derivative that is commonly used for inducing labor and as an abortifacient. It is used either alone or in combination with other medications like mifepristone for medical abortion. It can be administered orally, vaginally, or sublingually.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Dinoprost</strong>: Dinoprost is a naturally occurring prostaglandin F2-alpha (PGF2α), not a PGE1 derivative. It is also used in obstetrics but is not a synthetic PGE1 derivative.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;B. Dinoprostone</strong>: Like Dinoprost, Dinoprostone is another form of prostaglandin but it is a naturally occurring PGE2. It is also used in obstetrics to ripen the cervix and induce labor, but it is not a synthetic PGE1 derivative.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Carboprost</strong>: Carboprost is a synthetic analogue of prostaglandin F2-alpha (PGF2α). It is used to induce abortion and treat postpartum hemorrhage but is not a synthetic PGE1 derivative.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Therefore, the synthetic PGE1 derivative used as an abortifacient is Misoprostol, making option C the correct answer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Misoprostol is the synthetic PGE1 derivative used as an abortifacient. It is effective in inducing labor, facilitating medical abortion, and treating postpartum hemorrhage by promoting uterine contractions and cervical ripening.</span></p>",
      "correct_choice_id": 25843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7085,
      "choices": [
        {
          "id": 28308,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nivolumab</span></span></span></p>"
        },
        {
          "id": 28309,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pembrolizumab</span></span></span></p>"
        },
        {
          "id": 28310,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Trastuzumab</span></span></span></p>"
        },
        {
          "id": 28311,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ipilimumab</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which among the following drugs is the new FDA approved immune check point inhibitor for carcinoma endometrium?</span></span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q1064135",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137648,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. Pembrolizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The new FDA-approved immune checkpoint inhibitor for carcinoma endometrium is Pembrolizumab.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pembrolizumab is a monoclonal antibody against PD-1 receptor (Programmed Death Receptor) that can be used for many cancers including endometrial carcinoma. Some of the other cancers where it is useful are:</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metastatic urothelial cancer</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Refractory melanoma</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hodgkin&rsquo;s Lymphoma</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Merkel cell cancer</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chemotherapy Refractory Head and Neck Cancer</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Nivolumab:</strong> is an immune checkpoint inhibitor that acts by inhibiting programmed death receptor - 1 (PD-1) and is used for the treatment of advanced melanoma and relapsed/refractory classical Hodgkin lymphoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Trastuzumab: </strong>is a monoclonal antibody that inhibits the HER2 receptor. It is used in the treatment of HER2-positive breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> <strong>Ipilimumab:</strong> is a monoclonal antibody that binds to cytotoxic T lymphocyte-associated Protein 4 (CTLA-4) and is approved for the treatment of late-stage melanoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pembrolizumab is the new FDA-approved immune checkpoint inhibitor for carcinoma endometrium. It works by blocking the PD-1 receptor, enhancing the immune system&#39;s ability to attack cancer cells. It is also used for treating several other cancers, including metastatic urothelial cancer, refractory melanoma, Hodgkin&rsquo;s lymphoma, Merkel cell cancer, and chemotherapy-refractory head and neck cancer.</span></span></span></p>",
      "correct_choice_id": 28309,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7036,
      "choices": [
        {
          "id": 28112,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bradycardia with AV block</span></span></span></p>"
        },
        {
          "id": 28113,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Torsades&rsquo; de pointes</span></span></span></p>"
        },
        {
          "id": 28114,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tachycardia</span></span></span></p>"
        },
        {
          "id": 28115,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ventricular fibrillation</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient was taking metoprolol for hypertension but blood pressure was not controlled. Verapamil was added to the regimen. Which of the following adverse effect is likely to be present with combination? (AIIMS MAY 2020)</span></span></p>",
      "unique_key": "Q1787323",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137649,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Bradycardia with AV block</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol is a beta-blocker that is commonly used to hypertension, heart failure, and arrhythmias. It works by slowing down the heart rate and reducing the heart&#39;s demand for oxygen.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil, on the other hand, is a calcium channel blocker used for similar indications as metoprolol. It reduces the heart rate and has a negative inotropic effect (reduces the force of heart muscle contraction), and can affect the electrical conduction in the heart.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When used together, metoprolol and verapamil can have additive effects on the heart rate and atrioventricular (AV) nodal conduction. This can lead to:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bradycardia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An abnormally slow heart rate.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AV block:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A delay or complete block in the electrical impulse conduction through the AV node of the heart.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Torsades de pointes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a specific type of ventricular tachycardia that is not typically associated with the combination of metoprolol and verapamil. It is more often related to medications that prolong the QT interval.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tachycardia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an increased heart rate, which is an unlikely side effect of combining metoprolol and verapamil, as both tend to slow the heart rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ventricular fibrillation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this is a serious cardiac arrhythmia, it is not a typical side effect of combining metoprolol and verapamil. It&#39;s more commonly associated with ischemic heart disease or other structural heart problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of metoprolol and verapamil can lead to significant bradycardia and AV block due to their additive effects on slowing heart rate and AV nodal conduction.</span></span></span></p>",
      "correct_choice_id": 28112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7053,
      "choices": [
        {
          "id": 28180,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2C19</span></span></span></p>"
        },
        {
          "id": 28181,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2D6</span></span></span></p>"
        },
        {
          "id": 28182,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Upregulation of CYP1A1</span></span></span></p>"
        },
        {
          "id": 28183,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Downregulation of CYP2E1</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of 45 year with history of ischemic stroke was started on clopidogrel, However, she had another attack of stroke after 6 months. Which of the following is likely to be responsible for the failure of clopidogrel in this patient? (INICET MAY 2021)</span></span></p>",
      "unique_key": "Q3096448",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137650,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Downregulation of CYP2C19</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clopidogrel is an antiplatelet drug used to prevent MI and stroke. The failure of clopidogrel in preventing a second stroke in a patient can be influenced by various factors, including genetic variations that affect drug metabolism. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is a prodrug that requires activation by CYP2C19. Genetic polymorphisms or downregulation of CYP2C19 can lead to reduced conversion of clopidogrel to its active form. This results in decreased antiplatelet activity and a higher risk of thrombotic events, such as stroke. Individuals with reduced function alleles of CYP2C19 are known as &quot;poor metabolizers,&quot; and in these patients, clopidogrel may be less effective.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Downregulation of CYP2D6</strong>: While CYP2D6 is important for the metabolism of many drugs, it is not primarily responsible for the activation of clopidogrel. Therefore, downregulation of CYP2D6 would not significantly impact clopidogrel&#39;s effectiveness.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Upregulation of CYP1A1</strong>: CYP1A1 is not involved in the metabolism of clopidogrel. Its upregulation would not affect the activation of clopidogrel or its therapeutic efficacy.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Downregulation of CYP2E1</strong>: CYP2E1 is involved in the metabolism of ethanol and certain other drugs but does not play a significant role in the activation of clopidogrel. Therefore, downregulation of CYP2E1 would not impact clopidogrel&#39;s effectiveness.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The failure of clopidogrel in preventing a second stroke in a patient may be due to the downregulation of CYP2C19. This enzyme is crucial for converting clopidogrel into its active form, and its reduced activity can lead to decreased antiplatelet effects and increased risk of thrombotic events.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/18/screenshot-2024-07-18-111759.png\" style=\"height:500px; width:1000px\" /></span></span></span></p>",
      "correct_choice_id": 28180,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6875,
      "choices": [
        {
          "id": 27468,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hyperprolactinemia</span></span></span></p>"
        },
        {
          "id": 27469,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PCOD</span></span></span></p>"
        },
        {
          "id": 27470,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypogonadotrophic hypogonadism</span></span></span></p>"
        },
        {
          "id": 27471,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">PID</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 27-year-old female came for treatment of infertility to OPD, Bromocriptine was prescribed. What could be the possible reason? (AIIMS NOV 2017)</span></span></p>",
      "unique_key": "Q9960925",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137651,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Hyperprolactinemia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bromocriptine is a dopamine agonist that acts on D2 receptors. It is effective in reducing prolactin secretion, which is useful in treating hyperprolactinemia. Elevated levels of prolactin can inhibit the secretion of gonadotropin-releasing hormone (GnRH), leading to decreased levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which can cause anovulation and infertility.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mechanism of Bromocriptine:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Action:</span></strong><span style=\"font-size:12.0pt\"> Bromocriptine stimulates D2 dopamine receptors.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Effect:</span></strong><span style=\"font-size:12.0pt\"> Decreases prolactin secretion from the pituitary gland.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Result:</span></strong><span style=\"font-size:12.0pt\"> Reduction in prolactin levels can restore normal GnRH secretion, normalizing FSH and LH levels and resuming ovulatory cycles, thus addressing infertility.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. PCOD (Polycystic Ovarian Disease):&nbsp;</span></strong><span style=\"font-size:12.0pt\">PCOD is characterized by multiple cysts in the ovaries, insulin resistance, and hyperandrogenism. Treatment usually involves lifestyle changes, metformin, or hormonal therapies, not specifically bromocriptine unless associated with hyperprolactinemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypogonadotrophic hypogonadism:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This condition involves low levels of FSH and LH due to hypothalamic or pituitary dysfunction. Treatment often includes gonadotropins or pulsatile GnRH therapy. Bromocriptine is not indicated unless hyperprolactinemia is a contributing factor.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PID (Pelvic Inflammatory Disease):&nbsp;</span></strong><span style=\"font-size:12.0pt\">PID is an infection of the female reproductive organs. Treatment typically involves antibiotics. Bromocriptine has no role in treating PID.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bromocriptine is a Dopaminergic agonist that leads to a decrease in the secretion of Prolactin by its action on the D2 dopaminergic receptors of the Nigrostriatal Pathway. Hyperprolactinemia can cause infertility by inhibiting the release of GnRH from the hypothalamus, leading to a decrease in the levels of FSH and LH.</span></span></span></p>",
      "correct_choice_id": 27468,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52313,
      "choices": [
        {
          "id": 208749,
          "text": "<p><span style=\"font-size:12.0pt;\">Delirium Tremens</span></p>"
        },
        {
          "id": 208750,
          "text": "<p><span style=\"font-size:12.0pt;\">Wernicke’s Encephalopathy</span></p>"
        },
        {
          "id": 208751,
          "text": "<p><span style=\"font-size:12.0pt;\">Korsakoff Psychosis</span></p>"
        },
        {
          "id": 208752,
          "text": "<p><span style=\"font-size:12.0pt;\">Alcohol Withdrawal Seizures</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient stopped alcohol 3 days ago, presented with irritability, altered sensorium, and visual hallucinations. What is the likely diagnosis?</span><span style=\"font-size:11pt;\"> </span><span style=\"font-size:12.0pt;\">(NEET PG 2021)</span></p>",
      "unique_key": "Q3220222",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137652,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. Delirium Tremens</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Delirium Tremens (DT) is a severe form of alcohol withdrawal that typically occurs 48-72 hours after the last drink. It is characterized by:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Autonomic instability (e.g., tachycardia, hypertension, hyperthermia)</span></li><li><span style=\"font-size:12.0pt;\">Severe agitation and irritability</span></li><li><span style=\"font-size:12.0pt;\">Altered sensorium (e.g., confusion, delirium)</span></li><li><span style=\"font-size:12.0pt;\">Visual and auditory hallucinations</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">DT is a medical emergency with high morbidity and mortality if not treated promptly.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The <strong>treatment of choice is benzodiazepines</strong>, which help to control agitation and prevent complications such as seizures. Long-acting benzodiazepines like diazepam are preferred unless there is liver dysfunction, in which case shorter-acting agents like lorazepam or oxazepam are used.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Special Considerations for Liver Impairment</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Cirrhosis or Severe Liver Failure</strong>: In patients with compromised liver function, the metabolism of drugs, particularly those processed by the liver, can be significantly impaired.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Short-Acting Drugs</strong>: Lorazepam is recommended as it is less reliant on hepatic oxidation and more on glucuronidation, which is relatively preserved in liver disease.</span></li><li><span style=\"font-size:12.0pt;\">Oxazepam is also suggested as it undergoes direct conjugation in the liver without the need for extensive metabolism, making it safer for patients with severe liver impairment.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Wernicke’s Encephalopathy:</strong> Wernicke’s Encephalopathy is caused by thiamine deficiency and presents with a triad of ophthalmoplegia, ataxia, and confusion. It does not typically present with hallucinations or irritability.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Korsakoff Psychosis:</strong> Korsakoff Psychosis is a chronic condition resulting from untreated Wernicke’s Encephalopathy, characterized by severe memory impairment/ amnesia and confabulation. It does not present acutely and lacks the autonomic instability seen in DT.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Alcohol Withdrawal Seizures:</strong> Alcohol withdrawal seizures typically occur within 6-48 hours after the last drink and present as generalized tonic-clonic seizures (GTCS). They do not present with the prolonged altered sensorium or hallucinations characteristic of DT.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Delirium Tremens is a severe alcohol withdrawal syndrome occurring 48-72 hours after cessation of alcohol intake, characterized by autonomic instability, severe agitation, altered sensorium, and hallucinations. It requires immediate treatment with benzodiazepines to manage symptoms and prevent complications.</span></p>",
      "correct_choice_id": 208749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9794,
      "choices": [
        {
          "id": 39143,
          "text": "<p><span style=\"font-size:12.0pt;\">Red</span></p>"
        },
        {
          "id": 39144,
          "text": "<p><span style=\"font-size:12.0pt;\">Grey</span></p>"
        },
        {
          "id": 39145,
          "text": "<p><span style=\"font-size:12.0pt;\">Blue</span></p>"
        },
        {
          "id": 39146,
          "text": "<p><span style=\"font-size:12.0pt;\">Yellow</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the color of vacutainer containing sodium fluoride as a content? (AIIMS NOV 2018)</span></p>",
      "unique_key": "Q7411311",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137653,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Grey</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The <strong>grey-colored vacutainer</strong> contains <strong>sodium fluoride</strong> as an anticoagulant. Sodium fluoride acts by inhibiting glycolysis, which is the breakdown of glucose by enzymes, releasing energy and pyruvic acid. By inhibiting this process, sodium fluoride preserves the glucose levels in the blood sample, making it ideal for the <strong>estimation of blood glucose and alcohol levels</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;A. Red</strong>: Red tubes typically do not contain an anticoagulant and are used for serum tests where the blood is allowed to clot before centrifugation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C. Blue</strong>: Blue tubes usually contain <strong>sodium citrate</strong> as an anticoagulant, used primarily for coagulation studies such as PT and PTT.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Yellow</strong>: Yellow tubes may contain <strong>ACD (acid-citrate-dextrose)</strong> or <strong>SPS (sodium polyanethol sulfonate)</strong>, used for blood cultures or blood bank studies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/05/screenshot-2024-09-05-184153.png\" alt=\"\" width=\"1000\" height=\"689\"></p>",
      "correct_choice_id": 39144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31807,
      "choices": [
        {
          "id": 127098,
          "text": "<p><span style=\"font-size:12pt;\">Hydroxyurea</span></p>"
        },
        {
          "id": 127099,
          "text": "<p><span style=\"font-size:12pt;\">Methotrexate plus leucovorin</span></p>"
        },
        {
          "id": 127100,
          "text": "<p><span style=\"font-size:12pt;\">Methionine</span></p>"
        },
        {
          "id": 127101,
          "text": "<p><span style=\"font-size:12pt;\">Eltrombopag</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following drugs is used to prevent painful vaso-occlusive crises and decrease long-term complications in sickle cell anemia? (INICET NOV 2023)</span></p>",
      "unique_key": "Q3783724",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137654,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Hydroxyurea.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Hydroxyurea is widely used in the management of sickle cell anemia. It helps to increase the concentration of fetal hemoglobin (HbF) in the bloodstream, which is less likely to participate in the sickling process that characterizes sickle cell disease. By reducing the sickling of red blood cells, hydroxyurea lowers the incidence of vaso-occlusive crises that cause pain and can lead to organ damage. Additionally, the drug has been shown to have a positive impact on the long-term complications associated with sickle cell anemia, including reducing the risk of stroke and other serious events.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Methotrexate plus leucovorin:</strong> This combination is not used for sickle cell anemia. Methotrexate is primarily used in the treatment of certain cancers and autoimmune diseases, and leucovorin is given to mitigate the side effects of methotrexate.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Methionine:</strong> Methionine is an essential amino acid that is not used to treat sickle cell anemia or its complications. It has no role in preventing vaso-occlusive crises. Rather L-glutamine is the amino acid that is used in sickle cell disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Eltrombopag:</strong> Eltrombopag is a medication that stimulates platelet production and is used in conditions like chronic immune thrombocytopenia. It is not indicated for the treatment or prevention of complications in sickle cell anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Hydroxyurea is the primary medication used to prevent painful vaso-occlusive crises and decrease long-term complications in sickle cell anemia by increasing the concentration of fetal hemoglobin (HbF).</span></p>",
      "correct_choice_id": 127098,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14405,
      "choices": [
        {
          "id": 57581,
          "text": "<p><span style=\"font-size:12.0pt;\">1-2%</span></p>"
        },
        {
          "id": 57582,
          "text": "<p><span style=\"font-size:12.0pt;\">3%</span></p>"
        },
        {
          "id": 57583,
          "text": "<p><span style=\"font-size:12.0pt;\">13-20%</span></p>"
        },
        {
          "id": 57584,
          "text": "<p><span style=\"font-size:12.0pt;\">20-30%</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old female patient undergoes surgery for a clean-contaminated wound after receiving prophylactic antibiotics. What is the expected rate of surgical site infection in this patient?</span> <span style=\"font-size:12.0pt;\">(AIIMS NOV 2019)</span></p>",
      "unique_key": "Q4161362",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137655,
      "difficulty_level": "intermediate",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) 3%</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">After the administration of prophylactic antibiotics, the anticipated rate of surgical site infection in a patient with a clean contaminated wound is 3%.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This is a reasonable estimate for the expected rate of SSI in clean-contaminated surgical wounds. These wounds have a controlled level of contamination, and prophylactic antibiotics are given to reduce the risk of infection.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>A. 1-2%</strong>: This range represents a lower infection rate, which is more commonly associated with surgeries in clean wounds.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. 13-20%</strong>: This range is much higher and is more typical for surgeries in contaminated or dirty wounds, where the risk of infection is significantly elevated.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D. 20-30%</strong>: This range represents a very high infection rate and is more characteristic of surgeries performed in dirty or heavily contaminated wounds. It would be unusual to expect such a high infection rate in a clean-contaminated surgical case with prophylactic antibiotics.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">A surgical site infection (SSI) is an infection that occurs at or near a surgical incision or operative site after surgery. SSIs can range from mild to severe and can affect the skin and underlying tissues, including muscles and organs. These infections are a common complication of surgery and can lead to various health problems if not treated promptly.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Key characteristics and considerations related to surgical site infections (SSIs) include:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Classification:</strong></span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">SSIs are classified into three main categories based on the timing of onset:</span></li><li><span style=\"font-size:12.0pt;\">Superficial Incisional SSI: Infection occurs within 30 days after the operation and involves only the skin and subcutaneous tissues at the incision site.</span></li><li><span style=\"font-size:12.0pt;\">Deep Incisional SSI: Infection also occurs within 30 days after the operation but involves deeper tissues, such as muscles and fascia, at the incision site.</span></li><li><span style=\"font-size:12.0pt;\">Organ/Space SSI: Infection can occur within 30 or 90 days after the operation and affects any part of the body other than the incision area. This can include infections within the abdominal or chest cavities.</span><br>&nbsp;</li></ul></li><li><span style=\"font-size:12.0pt;\"><strong>Signs and Symptoms:</strong></span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">The symptoms of an SSI may include redness, warmth, swelling, pain, and discharge at or near the surgical site.</span></li><li><span style=\"font-size:12.0pt;\">Systemic symptoms like fever, chills, and malaise can also occur if the infection is severe or has spread.</span><br>&nbsp;</li></ul></li><li><span style=\"font-size:12.0pt;\"><strong>Prevention:</strong></span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Preventive measures are crucial in reducing the risk of SSIs. These measures include:</span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Preoperative antibiotic prophylaxis</span></li><li><span style=\"font-size:12.0pt;\">Proper hand hygiene and sterile techniques during surgery</span></li><li><span style=\"font-size:12.0pt;\">Maintaining a clean surgical environment</span></li><li><span style=\"font-size:12.0pt;\">Adequate skin preparation before incision</span></li><li><span style=\"font-size:12.0pt;\">Proper wound care and postoperative monitoring</span><br>&nbsp;</li></ul></li></ul></li><li><span style=\"font-size:12.0pt;\"><strong>Treatment:</strong></span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Treatment of an SSI typically involves antibiotics to target the specific bacteria causing the infection.</span></li><li><span style=\"font-size:12.0pt;\">In some cases, additional interventions may be necessary, such as wound drainage, debridement (removal of infected tissue), or, rarely, reoperation.</span><br>&nbsp;</li></ul></li><li><span style=\"font-size:12.0pt;\"><strong>Complications:</strong></span><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">If left untreated or not managed appropriately, SSIs can lead to more serious complications, such as abscess formation, cellulitis, tissue necrosis, and the spread of infection to other parts of the body.</span></li></ul></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/screenshot-2023-11-20-154011.png\" alt=\"\" width=\"1000\" height=\"526\"></span></p>",
      "correct_choice_id": 57582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9877,
      "choices": [
        {
          "id": 39474,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Pulmonary infarction</span></span></span></p>"
        },
        {
          "id": 39475,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Diffuse alveolar damage</span></span></span></p>"
        },
        {
          "id": 39476,
          "text": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Endothelial injury</span></span></span></p>"
        },
        {
          "id": 39477,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Fibrin clots</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common lung finding in COVID 19 infection is? (INICET NOV 2020)</span></span></p>",
      "unique_key": "Q3987471",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137656,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Diffuse alveolar damage</span></strong> </span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Diffuse alveolar damage</span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"> may be seen in patients suffering from COVID-19.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">COVID-19 related histopathological changes in the lungs include:</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Incipient pulmonary damage in early-stage disease with intraalveolar edema, endothelial necrosis, microthrombosis, and endothelialitis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Pneumocyte type 2 hyperplasia</span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"> in exudative phase</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Multiple intraalveolar giant cells in exudative phase</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Hyaline membranes and solid fibrin deposits in exudative phase</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\">Thrombosis in small- to medium-sized vessels in early-stage lung disease</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Pulmonary infarction:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> While pulmonary infarctions may occur due to thromboembolism, they are not the primary lung finding in COVID-19.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Endothelial injury:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Endothelial injury does occur in COVID-19 and contributes to microvascular damage and thrombosis, but it is part of the broader picture of diffuse alveolar damage.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Fibrin clots:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Fibrin clots are seen in COVID-19 as part of the coagulopathy associated with the disease, but they are secondary findings within the context of DAD.</span></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-right:-9px\">&nbsp;</p>\r\n\r\n<p style=\"margin-right:-9px\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Diffuse alveolar damage&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">is the most common and significant lung finding in severe COVID-19 infection, leading to the clinical syndrome of ARDS.</span></span></span></p>",
      "correct_choice_id": 39475,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6906,
      "choices": [
        {
          "id": 27592,
          "text": "<p><span style=\"font-size:12.0pt;\">Endometriosis</span></p>"
        },
        {
          "id": 27593,
          "text": "<p><span style=\"font-size:12.0pt;\">Male infertility</span></p>"
        },
        {
          "id": 27594,
          "text": "<p><span style=\"font-size:12.0pt;\">Central precocious puberty</span></p>"
        },
        {
          "id": 27595,
          "text": "<p><span style=\"font-size:12.0pt;\">Prostate cancer</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"color:#333333;font-size:12pt;\">Non-pulsatile dose of GnRH agonist is used in all of the following conditions except? (AIIMS NOV 2019)</span></p>",
      "unique_key": "Q7178981",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137657,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"color:#333333;font-size:12pt;\"><strong>Ans. B. Male infertility</strong></span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\">Pulsatile exposure to GnRH induces FSH/LH secretion while sustained exposure de-sensitizes the receptors resulting in decrease in secretion of gonadotropins. Therefore, non-pulsatile (continuous) GnRH agonists are given when we want to decrease the sex hormones.</span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\"><strong>Indications:-</strong></span></p><p>&nbsp;</p><ul><li><span style=\"color:#333333;font-size:12pt;\">&nbsp;Prostatic carcinoma</span></li><li><span style=\"color:#333333;font-size:12pt;\">&nbsp;Endometriosis</span></li><li><span style=\"color:#333333;font-size:12pt;\">&nbsp;Precocious puberty</span></li><li><span style=\"color:#333333;font-size:12pt;\">&nbsp;Fibroid</span></li></ul><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\">But in case of male infertility, more testosterone is required to induce spermatogenesis, so GnRH agonists are given in pulsatile manner.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Endometriosis:&nbsp;</strong>In endometriosis, continuous GnRH agonists are used to lower estrogen levels, which helps reduce the growth of endometrial tissue and alleviate symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Central precocious puberty</strong></span><span style=\"font-size:12pt;\"><strong>:</strong></span><span style=\"font-size:14px;\"><strong>&nbsp;</strong></span><span style=\"font-size:12pt;\">Continuous GnRH agonists are used to decrease sex hormone levels, thereby delaying early onset puberty.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Prostate cancer:&nbsp;</strong>Continuous GnRH agonists reduce testosterone levels, which helps in managing prostate cancer by slowing down the growth of cancer cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Non-pulsatile (continuous) GnRH agonists are used to decrease sex hormone levels in conditions such as endometriosis, central precocious puberty, and prostate cancer. In male infertility, pulsatile GnRH agonists are used to increase testosterone and induce spermatogenesis.</span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\"><strong>Reference: KDT 8th/. 262,263</strong></span></p>",
      "correct_choice_id": 27593,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6963,
      "choices": [
        {
          "id": 27820,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluoxetine</span></span></span></p>"
        },
        {
          "id": 27821,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Venlafaxine</span></span></span></p>"
        },
        {
          "id": 27822,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mirtazapine</span></span></span></p>"
        },
        {
          "id": 27823,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Imipramine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following antidepressants causes the least sexual dysfunction? (INICET NOV 2020)</span></span></p>",
      "unique_key": "Q4502766",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137658,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Mirtazapine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The typical antidepressants (SSRI, SNRI, MAO inhibitors and TCA) are notorious for causing sexual disturbances like erectile dysfunction due to increased levels of serotonin. On the other hand, atypical anti-depressants (like mirtazapine and bupropion etc) have lesser propensity to cause these adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Options A. Fluoxetine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: As a selective serotonin reuptake inhibitor (SSRI), fluoxetine is commonly associated with sexual dysfunction, including decreased libido, difficulty achieving orgasm, and erectile dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Options B. Venlafaxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a serotonin-norepinephrine reuptake inhibitor (SNRI). While perhaps slightly less likely to cause sexual side effects than SSRIs, venlafaxine can still lead to sexual </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">dysfunction in a significant number of patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Options D. Imipramine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A tricyclic antidepressant (TCA), imipramine can cause sexual dysfunction, often due to its anticholinergic effects. TCAs, in general, are more likely to cause a variety of side effects, including those affecting sexual function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mirtazapine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an atypical antidepressant. Apart from increasing the levels of serotonin and nor-adrenaline (due to blockade of presynaptic alpha 2 receptors), It also acts as an antagonist of serotonin (5-HT2 and 5-HT3) receptors. It has some degree of H1 blocking property also. It is therefore known as NSSA (Nor adrenergic and Specific Serotonergic Antidepressant). Mirtazapine is generally associated with a lower incidence of sexual side effects compared to SSRIs and SNRIs, making it a better option for patients concerned about these issues.</span></span></span></p>",
      "correct_choice_id": 27822,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7027,
      "choices": [
        {
          "id": 28076,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Chlorthalidone</span></p>"
        },
        {
          "id": 28077,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Triamterene</span></p>"
        },
        {
          "id": 28078,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Spironolactone</span></p>"
        },
        {
          "id": 28079,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Furosemide</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"color:#333333;font-size:12.0pt;\">Preferred&nbsp;drug for the treatment of a 48-year-old man with uncomplicated grade 2 hypertension without any associated co-morbidity is (AIIMS MAY 2019)</span></p>",
      "unique_key": "Q9954479",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137659,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"color:#333333;font-size:12pt;\"><strong>Ans.&nbsp;A. Chlorthalidone</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Chlorthalidone</strong> is a thiazide-like diuretic that is highly effective in lowering blood pressure and is often recommended as the preferred first-line treatment for uncomplicated grade 2 hypertension. It has a longer duration of action compared to other thiazides, such as hydrochlorothiazide, making it particularly effective in managing hypertension over a 24-hour period.</span></li><li><span style=\"color:#333333;font-size:12pt;\">According to ACC Guidelines and JNC 8 Guidelines, the DOC for hypertension is Thiazides (preferred diuretic).</span></li><li><span style=\"color:#333333;font-size:12pt;\">Apart from thiazides, the other first line drugs for hypertension are-</span></li><li><span style=\"color:#333333;font-size:12pt;\">ACE Inhibitors</span></li><li><span style=\"color:#333333;font-size:12pt;\">Angiotensin receptor blockers</span></li><li><span style=\"color:#333333;font-size:12pt;\">Calcium channel blockers</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Triamterene</strong>: This is a potassium-sparing diuretic. It is primarily used in combination with other diuretics to prevent hypokalemia but is not recommended as a first-line treatment for hypertension.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Spironolactone</strong>: Another potassium-sparing diuretic, primarily used in conditions such as heart failure, hyperaldosteronism, and resistant hypertension, not as a first-line treatment for uncomplicated hypertension.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Furosemide</strong>: This is a loop diuretic, which is typically used in conditions such as congestive heart failure, renal insufficiency, and edema. It is not recommended as a first-line treatment for uncomplicated hypertension due to its short duration of action and the potential for significant electrolyte disturbances.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">For the treatment of uncomplicated grade 2 hypertension without any associated comorbidities, thiazide diuretics, particularly chlorthalidone, are the preferred first-line agents according to ACC and JNC 8 guidelines.</span></p><p>&nbsp;</p><p><span style=\"color:#333333;font-size:12pt;\"><strong>Reference: - KDT 8<sup>TH</sup>/615</strong></span></p>",
      "correct_choice_id": 28076,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7153,
      "choices": [
        {
          "id": 28580,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This action can be reversed by phenylephrine.</span></span></span></span></span></p>"
        },
        {
          "id": 28581,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿It cannot be reversed by levallorphan.</span></span></span></span></span></p>"
        },
        {
          "id": 28582,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\">﻿﻿﻿<span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is caused by activation of the Edinger-Westphal nucleus.</span></span></span></span></span></p>"
        },
        {
          "id": 28583,
          "text": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Tolerance develops to this adverse effect on long-term use.</span></span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of substance addiction is admitted to the hospital due to the overdose of the addictive substance. The patient has slow heart rate, respiratory depression, and low blood pressure. His ocular findings are shown below. Which of the following statements is true regarding this condition? (INICET NOV 2022)</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/06/750.jpg\" style=\"height:202px; width:300px\" /></span></span></span></span></span></p>",
      "unique_key": "Q2276188",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137660,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C.<span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is caused by activation of the Edinger-Westphal nucleus.</span></strong></span></span></span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pupil is constricted in the given image and as the history describes the patient to be an addict, who is brought to the hospital in an intoxicated state. The clinical features like pin-point pupils, bradycardia, hypotension, respiratory depression suggests that this is a case of opioid intoxication.</span></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Opioid induced miosis:</strong></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pupillary constriction caused by opioids result due to the activation of the Edinger Westphal Nucleus. Therefore, topical use of opioids in the eye does not induce miosis. It will be seen only on systemic administration of opioids. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The miosis induced by opioids cannot be reversed by mydriatic drugs like phenylephrine or anticholinergic drugs. Rather it can be reversed by opioid antagonists like naloxone and levallorphan.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolerance does not develop to opioid induced miosis even on long term use. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:9pt\"><span style=\"font-family:Helvetica,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. This action can be reversed by phenylephrine</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Phenylephrine is a mydriatic agent that causes dilation of the pupil by stimulating alpha-1 adrenergic receptors. It would not reverse opioid-induced miosis, which is due to central nervous system effects rather than direct effects on the iris muscles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B. It cannot be reversed by levallorphan</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Levallorphan is an opioid antagonist that can reverse the effects of opioid toxicity, including miosis. Therefore, this statement is incorrect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D. Tolerance develops to this adverse effect on long-term use:</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tolerance to opioid-induced miosis does not typically develop, even with long-term use of opioids. Therefore, this statement is incorrect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Opioid-induced miosis is caused by activation of the Edinger-Westphal nucleus, and it is a characteristic sign of opioid intoxication. This effect cannot be reversed by phenylephrine, and tolerance does not develop to this effect with long-term opioid use. Opioid antagonists like naloxone and levallorphan can reverse the miosis caused by opioid overdose</span></span></span></p>",
      "correct_choice_id": 28582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20840,
      "choices": [
        {
          "id": 83324,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Ziprasidone</span></p>"
        },
        {
          "id": 83325,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Clozapine</span></p>"
        },
        {
          "id": 83326,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Risperidone</span></p>"
        },
        {
          "id": 83327,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Aripiprazole</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A patient with schizophrenia, who did not respond to haloperidol and thioridazine, was started on drug A. After beginning treatment with drug A, the patient's psychotic symptoms improved; however, he developed sialorrhea, dyslipidemia, weight gain, and hyperglycemia. Which drug is most likely to be 'drug A'?&nbsp;</span>(NEET PG 2023)</p>",
      "unique_key": "Q5946846",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137661,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Clozapine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The description of the patient's response and side effects suggests that 'drug A' is most likely <strong>Clozapine</strong>. Clozapine is known for its effectiveness in <u>treatment-resistant schizophrenia</u>, where other antipsychotics like haloperidol and thioridazine have failed. It is distinguished by its side effect profile, which includes sialorrhea (excessive salivation), significant weight gain, dyslipidemia (abnormal lipid levels), and hyperglycemia (high blood sugar). These side effects are more pronounced with Clozapine compared to other antipsychotics.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;A. Ziprasidone:&nbsp;</strong>While it is an atypical antipsychotic, Ziprasidone is less likely to cause significant weight gain and metabolic side effects compared to Clozapine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C. Risperidone:&nbsp;</strong>Risperidone can cause weight gain and metabolic side effects, but it is less likely to cause sialorrhea and is not as commonly used in treatment-resistant schizophrenia as Clozapine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Aripiprazole: </strong>Aripiprazole is known for having a more favorable metabolic side effect profile and is less likely to cause significant weight gain, dyslipidemia, and hyperglycemia compared to Clozapine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In the treatment of treatment-resistant schizophrenia, Clozapine is often effective where other antipsychotics have failed. However, its use is associated with notable side effects including sialorrhea, significant weight gain, dyslipidemia, and hyperglycemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/23/120.jpg\" alt=\"\" width=\"1000\" height=\"739\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 222-224.</strong></span></p>",
      "correct_choice_id": 83325,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6930,
      "choices": [
        {
          "id": 27688,
          "text": "<p><span style=\"font-size:12.0pt;\">Ketoconazole</span></p>"
        },
        {
          "id": 27689,
          "text": "<p><span style=\"font-size:12.0pt;\">Indinavir</span></p>"
        },
        {
          "id": 27690,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamivudine</span></p>"
        },
        {
          "id": 27691,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with AIDS was treated with zidovudine, lamivudine, indinavir, ketoconazole and cotrimoxazole. He developed nephrolithiasis, central obesity, hyperlipidemia and insulin resistance. Which of the drugs could have been the cause? (AIIMS NOV 2018)</span></p>",
      "unique_key": "Q8894092",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137662,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Indinavir</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Indinavir is a protease inhibitor used in the treatment of HIV/AIDS. It is known for several side effects, which include nephrolithiasis (kidney stones), central obesity, hyperlipidemia, and insulin resistance. These adverse effects are part of the metabolic complications often associated with protease inhibitors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ketoconazole:&nbsp;</strong>Ketoconazole is an antifungal agent that does not typically cause nephrolithiasis, central obesity, hyperlipidemia, or insulin resistance. Its side effects are more related to hepatotoxicity, adrenal insufficiency, and drug interactions due to CYP3A4 inhibition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Lamivudine:&nbsp;</strong>Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV/AIDS. It is not commonly associated with nephrolithiasis, central obesity, hyperlipidemia, or insulin resistance. Its side effects can include lactic acidosis and hepatic steatosis, but these are less common.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Zidovudine:&nbsp;</strong>Zidovudine, another NRTI, is associated with side effects such as anemia, neutropenia, and myopathy but not with the specific metabolic complications listed (nephrolithiasis, central obesity, hyperlipidemia, insulin resistance).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Indinavir, a protease inhibitor used in HIV/AIDS treatment, is the drug responsible for causing nephrolithiasis, central obesity, hyperlipidemia, and insulin resistance among the medications listed.</span></p>",
      "correct_choice_id": 27689,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56332,
      "choices": [
        {
          "id": 224741,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Zidovudine</span></span></span></p>"
        },
        {
          "id": 224742,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adefovir</span></span></span></p>"
        },
        {
          "id": 224743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abacavir</span></span></span></p>"
        },
        {
          "id": 224744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tenofovir</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old man with a long-standing history of chronic hepatitis B presents to the infectious disease clinic after receiving a recent diagnosis of HIV. He reports feeling well overall but is worried about managing both infections simultaneously, as he has heard that some medications can be used to treat both conditions. He is interested in a treatment plan that simplifies his regimen to avoid multiple drugs. The doctor explains that certain medications can target both HIV and HBV, improving treatment adherence and efficacy. After a thorough discussion, the physician prescribes a drug known for its dual action against both viruses. Which of the following antiviral drugs has dual activity against both HIV and HBV?</span></span></span></p>",
      "unique_key": "Q8061465",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137953,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tenofovir</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) that is highly effective against both HIV and hepatitis B virus (HBV). It inhibits viral DNA synthesis, thus reducing replication of both viruses, making it a crucial choice in the treatment of co-infected patients. Tenofovir&rsquo;s dual action simplifies therapy, improves patient adherence, and provides a strong resistance barrier, making it a preferred option. Other NRTIs with similar dual activity include Lamivudine and Emtricitabine, which are often used in combination with Tenofovir for enhanced therapeutic benefits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Zidovudine</span></strong><span style=\"font-size:12.0pt\">: Zidovudine is an NRTI used for treating HIV but does not have activity against HBV. It is not suitable for managing patients with both infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adefovir</span></strong><span style=\"font-size:12.0pt\">: Adefovir is used primarily for HBV treatment but lacks sufficient efficacy against HIV, making it ineffective in co-infected patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Abacavir</span></strong><span style=\"font-size:12.0pt\">: Abacavir is effective against HIV but has no action against HBV. It is not used in managing co-infection where dual antiviral action is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tenofovir is a key antiviral agent with dual activity against both HIV and HBV, making it essential in managing co-infected patients. Recognizing drugs with combined efficacy, such as Lamivudine, and Emtricitabine, Tenofovir (Mnemonic: LET act against both) is crucial for optimizing treatment strategies and improving patient outcomes in cases of viral co-infections.</span></span></span></p>",
      "correct_choice_id": 224744,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5735,
      "choices": [
        {
          "id": 22912,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The quantity of sperms</span></span></span></p>"
        },
        {
          "id": 22913,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The motility of sperms</span></span></span></p>"
        },
        {
          "id": 22914,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The morphology of sperms</span></span></span></p>"
        },
        {
          "id": 22915,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of sperm</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the best parameter to assess in case of male infertility?&nbsp;</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(AIIMS NOV 2017)</span></span></span></span></p>",
      "unique_key": "Q7035677",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137954,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) The morphology of sperms</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The morphology of sperms is considered the best parameter to assess male infertility. Sperm morphology refers to the size and shape of sperm, and abnormalities in these characteristics can significantly affect a man&#39;s fertility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key Points:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm Morphology:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterization of normal sperm morphology shows improved correlation with fertilization rates during IVF cycles. A significantly decreased fertilization rate is observed when the normal morphology of the sample falls below the strict criteria of 4%.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm Quantity and Number:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While the quantity and number of sperms are important, they are not as critical as morphology in determining fertility potential.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm Motility:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Motility is also a crucial factor, but morphology has a stronger correlation with fertilization success.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. The quantity of sperms:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Refers to the total volume of ejaculate, which is less indicative of fertility compared to morphology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The motility of sperms:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Important for fertility but not as strongly correlated with fertilization success as morphology.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. The number of sperm:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Similar to the quantity, the number is important but does not correlate as closely with fertilization rates as morphology does.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sperm morphology is the most significant parameter for assessing male infertility, as it closely correlates with fertilization rates during assisted reproductive techniques like IVF.</span></span></span></p>",
      "correct_choice_id": 22914,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20910,
      "choices": [
        {
          "id": 83604,
          "text": "<p><span style=\"font-size:12.0pt;\">Sacubitril</span></p>"
        },
        {
          "id": 83605,
          "text": "<p><span style=\"font-size:12.0pt;\">Omapatrilat</span></p>"
        },
        {
          "id": 83606,
          "text": "<p><span style=\"font-size:12.0pt;\">Losartan</span></p>"
        },
        {
          "id": 83607,
          "text": "<p><span style=\"font-size:12.0pt;\">Nesiritide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Name the drug that acts on both the marked points: (NEET PG 2023)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/10/picture3.jpg\" alt=\"\" width=\"700\" height=\"488\"></span></p>",
      "unique_key": "Q1848764",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137955,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B)&nbsp;Omapatrilat</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Omapatrilat is a inhibits both neprilysin and Angiotensin-converting enzyme (ACE). As a result, there is a decrease in Angiotensin II and increase in natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Sacubitril:&nbsp;</strong>Sacubitril inhibits neprilysin reducing breakdown of vasoactive peptides such as natriuretic peptides and bradykinin, therefore increasing their levels leading to vasodilation, diuresis, and counteracting the effects of RAAS. Sacubitril is combined with an ARB, valsartan is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Losartan</strong>:<strong> </strong>Losartan is classified under angiotensin receptor blocker, used in the treatment of hypertension. A/E are Hyperkalemia, Dysgeusia, Postural hypotension. C/I in pregnancy, B/L Renal Artery Stenosis. Losartan decreases serum uric acid levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong></span><span style=\"font-size:14.6667px;\"><strong>&nbsp;</strong></span><span style=\"font-size:12.0pt;\"><strong>Nesiritide:</strong></span><span style=\"font-size:12pt;\"> Nesiritide is a synthetic brain natriuretic peptide (BNP), acts as a natriuretic and vasodilator. Primarily used in acute decompensated heart failure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Omapatrilat inhibits both neprilysin and angiotensin-converting enzyme, thereby decreasing angiotensin II and increasing natriuretic peptides, promoting natriuresis, diuresis, and vasodilation.</span></p>",
      "correct_choice_id": 83605,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6992,
      "choices": [
        {
          "id": 27936,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Safety</span></span></span></p>"
        },
        {
          "id": 27937,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Efficacy</span></span></span></p>"
        },
        {
          "id": 27938,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Potency</span></span></span></p>"
        },
        {
          "id": 27939,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Toxicity</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Therapeutic index is used for assessing which of the following factors? (AIIMS MAY 2018)</span></span></span></p>",
      "unique_key": "Q4320258",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137956,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Safety</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Therapeutic Index tells us about the margin of safety for a drug. It is calculated as follows:</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Therapeutic index = TD50/ED50</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&bull; TD50 (Median toxic dose) = Dose at which there were toxic effects at 50% of the subjects</span></span></span></p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&bull; ED50 (Median effect dose) = Dose required to produce a therapeutic effect in 50% of the individuals.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<h3><span style=\"font-size:13.5pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></h3>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Efficacy</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Efficacy refers to the maximum effect a drug can produce, regardless of dose. The therapeutic index does not measure this.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Potency</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Potency is the amount of drug needed to produce a given effect. It is not assessed by the therapeutic index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. <strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Toxicity</span></strong></span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While toxicity is a component of the therapeutic index (TD50), the index itself is used to measure the safety margin rather than toxicity alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The therapeutic index is used to assess the safety of a drug, indicating the margin between effective and toxic doses. A higher therapeutic index means a drug is safer, with a lower risk of adverse effects at therapeutic doses.</span></span></span></p>",
      "correct_choice_id": 27936,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6523,
      "choices": [
        {
          "id": 26061,
          "text": "<p><span style=\"font-size:12.0pt;\">Ondansetron</span></p>"
        },
        {
          "id": 26062,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoclopramide</span></p>"
        },
        {
          "id": 26063,
          "text": "<p><span style=\"font-size:12.0pt;\">Meclizine</span></p>"
        },
        {
          "id": 26064,
          "text": "<p><span style=\"font-size:12.0pt;\">Scopolamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An antiemetic was given to a chemotherapy patient, who then developed symptoms such as acute dystonia, bradykinesia, and tremors. Which of the following medications would have resulted in these symptoms? (NEET PG 2022)</span></p>",
      "unique_key": "Q2354743",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137957,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Metoclopramide</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Metoclopramide is an antiemetic and a prokinetic drug that acts by blocking the D2 receptors. It can be given IV and it can cross the Blood brain barrier, thereby leading to D2 receptor block in the brain which can have side effects like acute dystonia, abnormal movements and drug induced Parkinsonism.</span></li><li><span style=\"font-size:12.0pt;\">In such cases, to treat them, drugs having central anticholinergic action like Benzhexol are used. They work by resorting the balance that has been disrupted by having a relative cholinergic excess in the striatum due to dopaminergic blockade.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ondansetron:&nbsp;</strong>Ondansetron is a serotonin 5-HT3 receptor antagonist. It is commonly used as an antiemetic, especially in chemotherapy-induced nausea and vomiting, but it does not cause extrapyramidal side effects like metoclopramide. Its side effect profile mainly includes headaches, constipation, and QT prolongation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Meclizine:&nbsp;</strong>Meclizine is an antihistamine with anticholinergic properties, used primarily to treat motion sickness and vertigo. It does not block dopamine receptors and therefore does not cause extrapyramidal symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Scopolamine:&nbsp;</strong>Scopolamine is an anticholinergic drug used to prevent nausea and vomiting, particularly motion sickness. It works by blocking acetylcholine receptors and does not cause extrapyramidal symptoms. Its side effects include dry mouth, dizziness, and blurred vision.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Metoclopramide, an antiemetic that acts by blocking D2 receptors, can cause extrapyramidal symptoms such as acute dystonia, bradykinesia, and tremors.</span></p>",
      "correct_choice_id": 26062,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24711,
      "choices": [
        {
          "id": 98805,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ratio of the median lethal dose to the median effective dose in an individual. </span></span></span></p>"
        },
        {
          "id": 98806,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The range of doses at which a drug is effective without causing significant adverse effects. </span></span></span></p>"
        },
        {
          "id": 98807,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ratio of the median lethal dose to the median effective dose in a population. </span></span></span></p>"
        },
        {
          "id": 98808,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dosage at which a drug is both safe and effective in the majority of patients.</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clinical </span><span style=\"font-size:12.0pt\">Therapeutic Index of a drug is best described as:&nbsp;</span></span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q3673197",
      "question_audio": null,
      "question_video": null,
      "map_id": 12137958,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C. The ratio of the median lethal dose to the median effective dose in a population.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index of a drug is best described as the ratio of the median lethal dose (LD50) to the median effective dose (ED50). Both LD50 and ED50 are calculated by checking different doses in a population. </span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It represents the margin of safety of a drug. A higher Clinical Therapeutic Index indicates that a drug has a greater margin of safety, and can be given at higher doses without causing significant adverse effects. </span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index is an important consideration in the development and use of new medications, and helps healthcare providers determine the appropriate dose for individual patients.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px; text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. The ratio of the median lethal dose to the median effective dose in an individual</span></strong><span style=\"font-size:12.0pt\">: This description is incorrect because the therapeutic index is determined based on population data, not individual data.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. The range of doses at which a drug is effective without causing significant adverse effects</span></strong><span style=\"font-size:12.0pt\">: This describes the therapeutic window or therapeutic range, not the therapeutic index.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The dosage at which a drug is both safe and effective in the majority of patients</span></strong><span style=\"font-size:12.0pt\">: This is a general description of an effective and safe dosage regimen but does not specifically describe the therapeutic index.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Clinical Therapeutic Index of a drug is the ratio of the median lethal dose (LD50) to the median effective dose (ED50) in a population, representing the drug&#39;s margin of safety. A higher Therapeutic Index indicates a greater margin of safety.</span></span></span></p>",
      "correct_choice_id": 98807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6876,
      "choices": [
        {
          "id": 27472,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
        },
        {
          "id": 27473,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
        },
        {
          "id": 27474,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lithium</span></span></span></p>"
        },
        {
          "id": 27475,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which is a mood stabilizer with an anti-suicidal role? (AIIMS NOV 2017)</span></span></span></p>",
      "unique_key": "Q7540439",
      "question_audio": null,
      "question_video": null,
      "map_id": 12154809,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C. Lithium</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lithium is the only mood stabilizer that has been consistently shown to have an anti-suicidal effect in patients with bipolar disorder and major depressive disorder. Numerous studies have demonstrated that lithium reduces the risk of suicide and suicide attempts. It is considered the gold standard for mood stabilization, particularly in bipolar disorder, due to its efficacy in preventing both manic and depressive episodes.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mechanism of Lithium:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mood Stabilization:</span></strong><span style=\"font-size:12.0pt\"> Lithium modulates neurotransmission by affecting various neurotransmitter pathways, including serotonin and norepinephrine.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Neuroprotective Effects:</span></strong><span style=\"font-size:12.0pt\"> Lithium enhances neurogenesis and has neuroprotective effects, potentially contributing to its anti-suicidal properties.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reduction in Aggression and Impulsivity:</span></strong><span style=\"font-size:12.0pt\"> Lithium has been shown to reduce aggression and impulsivity, which are risk factors for suicide.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Carbamazepine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Carbamazepine is an anticonvulsant and mood stabilizer used to treat bipolar disorder, particularly in patients with rapid cycling or mixed states. However, it does not have a proven anti-suicidal effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lamotrigine:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Lamotrigine is effective as a mood stabilizer, particularly in preventing depressive episodes in bipolar disorder. While it helps in mood stabilization, it does not have a specific anti-suicidal effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Valproate:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Valproate is another anticonvulsant and mood stabilizer used in bipolar disorder, especially effective in rapid cyclers. It does not have an established anti-suicidal role.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lithium is unique among mood stabilizers for its anti-suicidal properties. It significantly reduces the risk of suicide and is effective in stabilizing mood in patients with bipolar disorder and major depressive disorder. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate is the drug of choice in rapid cyclers, whereas Lamotrigine is effective as a mood stabilizer in Depression.</span></span></span></p>",
      "correct_choice_id": 27474,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7128,
      "choices": [
        {
          "id": 28480,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug A decreases intestinal absorption of Drug B</span></p>"
        },
        {
          "id": 28481,
          "text": "<p><span style=\"font-size:9pt;\">﻿﻿﻿</span><span style=\"font-size:12.0pt;\">Drug A reduces first pass metabolism of Drug B</span></p>"
        },
        {
          "id": 28482,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿Drug A increases the metabolism of Drug B</span></p>"
        },
        {
          "id": 28483,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug A increases renal elimination of Drug B</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The table below gives the AUC of drug B alone and that of drug B when combined with another drug A. If the p value is &lt;0.01, then which of the following statements is true? (INICET 2021)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/14/screenshot-2023-12-14-170654.jpg\" alt=\"\" width=\"700\" height=\"190\"></span></p>",
      "unique_key": "Q6184777",
      "question_audio": null,
      "question_video": null,
      "map_id": 12154810,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B.&nbsp;Drug A reduces first pass metabolism of Drug B</strong></span><br>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The area under the curve or AUC in plasma concentration vs time graph can be used as a measure of the bioavailability of a drug. The bioavailability of a given drug refers to the fraction of the given dose which reaches the systemic circulation. The greater the area under the curve or AUC, the greater is the bioavailability.</span></li><li><span style=\"font-size:12.0pt;\">From the given data, it is seen that the AUC for Drug B is less than the AUC for Drug A + Drug B. And the p value &lt;0.01 indicates that the data is statistically significant. (As the p value is &lt;0.05)</span></li><li><span style=\"font-size:12.0pt;\">So, it can be inferred that the Drug A increases the bioavailability of drug B.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">As bioavailability depends on two factors:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Absorption (Bioavailability is directly proportional to the rate of drug absorption)</span></li><li><span style=\"font-size:12.0pt;\">First Pass Metabolism (Bioavailability is inversely proportional to the rate of first pass metabolism of the drug)</span></li><li><span style=\"font-size:12.0pt;\">Therefore, it can be assumed that drug B either increase the absorption or decrease the first pass metabolism of drug A.</span></li><li><span style=\"font-size:12.0pt;\">So among the given options, best answer seem to be option B: Drug A reduces the first pass metabolism of drug B</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Drug A decreases intestinal absorption of Drug B</strong>: This statement is incorrect. If Drug A decreased the intestinal absorption of Drug B, the AUC would be lower when the drugs are combined, not higher.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Drug A increases the metabolism of Drug B</strong>: This statement is incorrect. If Drug A increased the metabolism of Drug B, the AUC would be lower when the drugs are combined.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Drug A increases renal elimination of Drug B</strong>: This statement is incorrect. If Drug A increased the renal elimination of Drug B, it would lead to a decrease in AUC, not an increase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The increase in the AUC of Drug B when combined with Drug A, with a statistically significant p value, indicates that Drug A reduces the first pass metabolism of Drug B, thereby increasing its bioavailability.</span></p>",
      "correct_choice_id": 28481,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}